Compositions and methods for drug delivery
By designing polymer nanoparticles to associate with functional groups that allow permeability to the blood-brain barrier, and by using polymer shells with structures similar to choline and acetylcholine to encapsulate drugs, the problem of drugs being unable to cross the blood-brain barrier in existing technologies has been solved, and efficient drug delivery to the central nervous system has been achieved.
Patent Information
- Application Number
- CN202410906617.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-11-29
- Filing Date
- 2018-11-29
- Publication Date
- 2024-11-15
AI Technical Summary
Existing technologies are unable to effectively cross the blood-brain barrier, resulting in low efficiency in the delivery of drugs for the treatment of central nervous system diseases.
Develop polymer nanoparticles by associating a cross-linked polymer matrix with various bioactive drugs and functional groups that increase blood-brain barrier permeability to form polymer nanomaterials. Utilize polymer shells with structures similar to choline and acetylcholine to encapsulate drugs and achieve rapid pathway delivery.
It improves the efficiency of drugs crossing the blood-brain barrier, enables effective drug delivery within the central nervous system, and enhances therapeutic effects.
Smart Images

Figure CN118948797A_ABST
Abstract
Description
Background Art
[0001] Central nervous system (CNS) related diseases and dysfunctions have become one of the main causes of death in humans worldwide. The blood-brain barrier (BBB) is a barrier between blood and brain tissue, which can limit the free exchange of substances between blood and brain tissue, prevent harmful substances from entering brain tissue, and protect the central nervous system such as brain and spinal cord (Banks, WA, Nat. Rev. Drug. Discov. 15, 275-292 (2016); Abot, NJ, Ronback, L. & Hanson, E., Nat. Rev. Neurosci. 7, 41-53 (2006)). However, the existence of the blood-brain barrier also hinders the development of drugs for the treatment of the central nervous system. Although some small molecules can use intercellular hydrophilic transport pathways and transcellular lipophilic transport pathways, as well as transport proteins, to cross the blood-brain barrier, biological macromolecules crossing the blood-brain barrier usually rely on receptor-mediated or adaptive endocytosis. Receptor-mediated endocytosis is often limited to specific endogenous molecules, while adaptive transport pathways often have poor transport efficiency.
[0002] Currently, there are many strategies to enhance the ability to cross the blood-brain barrier, including (1) increasing the circulation time of therapeutic drugs; (2) achieving adsorption-mediated endocytosis of therapeutic drugs through chemical modification; (3) conjugating peptide molecules or peptidomimetic monoclonal antibodies (mAB) to induce receptor-mediated endocytosis; (4) using "Trojan Horse" carriers to transport therapeutic antibodies; (5) using transport immune cells to deliver therapeutic drugs; (6) using physical methods such as ultrasound to open the tight channels of the blood-brain barrier. However, due to their own limitations, the efficiency of crossing the blood-brain barrier and drug delivery of these reported methods is still very low.
[0003] Therefore, developing effective molecular transport strategies to cross the blood-brain barrier is one of the key issues that need to be urgently addressed in the treatment of central nervous system diseases. Summary of the invention
[0004] Definition 1: The present invention provides a class of polymer nanoparticles, which include a cross-linked polymer matrix, a plurality of bioactive drugs, and a plurality of polymer nanomaterials with functional groups that can increase the permeability of the blood-brain barrier. Specifically, the copolymer includes polymer monomers, and the group associated with each drug monomer is associated with the drug in a non-covalent bonding manner.
[0005] Definition 2: The present invention provides a type of polymer nanoparticles, which include a cross-linked polymer, a plurality of bioactive drugs covalently coupled to the polymer, and a plurality of functional groups coupled to the polymer for increasing the permeability of the blood-brain barrier.
[0006] Definition three, the present invention provides a polymer bioactive drug copolymer, which comprises a bioactive drug, a plurality of polymers covalently coupled to the bioactive drug, and a plurality of functional groups coupled to the polymers for increasing the permeability of the blood-brain barrier. BRIEF DESCRIPTION OF THE DRAWINGS
[0007] Figure 1 Molecular structures of acetylcholine, choline, 2-methacryloyloxyethyl phosphorylcholine, and quaternized dimethylaminoethyl methacrylate, and schematic diagram of potential binding mechanisms to acetylcholine receptors. Circles indicate structural similarities.
[0008] Figure 2A .Schematic diagram of the synthesis of BBB-penetrating protein nanoparticles. Monomers and cross-linkers are polymerized in situ to form nanoparticles that encapsulate protein molecules; the MPC molecules in the nanoparticles enable the nanoparticles to effectively penetrate the BBB. After the cross-linker in the nanoparticles is degraded, the therapeutic protein can be released into the central nervous system.
[0009] Figure 2B . Schematic diagram of the synthesis of BBB-penetrating therapeutic drugs by conjugating polymer chains with ChT or nAchRs-like structures with therapeutic molecules such as proteins.
[0010] Figure 3A .Representative TEM images of HRP nanoparticles.
[0011] Figure 3B Representative TEM images of macaque CSF. CSF samples were collected on the first day after intravenous injection of 10.0 mg / kg n-HRP nanoparticles.
[0012] Figure 3C .Concentrations of n-HRP in macaque CSF recorded at different doses. The results show that the delivery of n-HRP is dose-dependent.
[0013] Figure 3D . Pharmacokinetics of n-HRP at different doses (2.5, 5 and 10 mg / mL) in macaque plasma.
[0014] Figure 3E The delivery efficiency of n-HRP was such that the concentration in CSF was as high as 5.3% of the plasma concentration.
[0015] Figure 3F. The penetration ability of n-BSA prepared with different monomers through the BBB permeation model in vitro. QDMAEMA represents quaternized dimethylaminoethyl methacrylate.
[0016] Figure 4A . Rituximab concentrations in macaque plasma following intravenous administration of native rituximab and rituximab nanoparticles (n-rituximab).
[0017] Figure 4B . Rituximab concentrations in the cerebrospinal fluid of macaques following intravenous administration of native rituximab and nanorituximab (n-rituximab).
[0018] Figure 5A Bioluminescence imaging (BLI) of nude mice bearing orthotopic gliomas in different treatment groups. Images were recorded on days 10, 20, 30, 40, and 50 after tumor implantation. Mice given native nimotuzumab had tumors of similar size to the untreated group, whereas mice given n(nimotuzumab) had significantly smaller tumors. Figure 5B .H&E staining of nude mouse orthotopic glioma brain sections in different treatment groups.
[0019] Figure 5C .BLI quantification of orthotopic glioma size in nude mice with different treatment groups.
[0020] Figure 5D .Survival rate of mice in different treatment groups. Kaplan-Meier analysis method was used. *p<0.05 Fig. 6A Optical imaging of mouse brain 1 day after intravenous injection of PBS, native BSA (C-nBSA-1), and BSA conjugate (C-nBSA-2).
[0021] Figure 6B Quantification of fluorescence intensity in mouse brain 1 day after intravenous injection of PBS, native BSA (C-nBSA-1), and BSA conjugate (C-nBSA-2).
[0022] Fig. 7A .Bioluminescence imaging of mice bearing orthotopic U87-EGFRwt glioma xenografts, and ex vivo fluorescence images of the mouse brain 4 hours after a one-time injection of 5 mg / kg Cy5.5-labeled n(Nimo) with different MPC contents.
[0023] Figure 7B . Relative fluorescence intensity of glioma brain tissue 4 hours after a single injection of 5 mg / kg Cy5.5 labeled n(Nimo) with different MPC contents. *p<0.05 and ***p<0.001 (one-way ANOVA). Fig. 8ABioluminescence imaging of mice bearing orthotopic U87-EGFRwt glioma xenografts and ex vivo fluorescence images of dissected brains 4 hours after a one-time injection of 5 mg / kg Cy5.5-labeled n(Nimo). Mice were pre-injected intraperitoneally with different doses of hemicholinium-3 (HC-3) 20 minutes before the injection of n(Nimo).
[0024] Figure 8B .Relative fluorescence intensity of glioma brain tissue 4 hours after a single injection of 5 mg / kg Cy5.5-labeled n(Nimo). Mice were intraperitoneally injected with different doses of hemicholinium-3(HC-3) 20 minutes before n(Nimo) injection. *p<0.05 and ***p<0.001 (normal one-way ANOVA). Fig. 9A Bioluminescence imaging of ischemic (transient focal cerebral ischemia) model rats (upper panel) and ex vivo fluorescence images of brain tissues collected (lower panel) 24 hours after intravenous injection of 0.5 mg / kg miR-21 Cy5.5-labeled miR-21 nanocapsules (n(Cy5.5-miR-21)).
[0025] Fig. 9B . ROI analysis of fluorescent signals and mature miR-21 levels in collected brain tissues. Data are presented as mean ± SD (n = 5). *P < 0.05 and **P < 0.001 (ordinary two-way ANOVA followed by Turkey post hoc).
[0026] Fig. 10A .Representative fluorescent images of ischemic hemisphere brain tissue 24 hours after intravenous injection of FITC-labeled miR-21 nanocapsules (n(FITC-miR-21)) at a dose of 0.5 mg / kg miR-21. An equal volume of PBS was used as a control. Green represents FITC-labeled miR-21. Brain sections were counterstained for nuclei with Hoechst and neurons with neuron-specific enolase (NSE). Scale bar: 100 μm.
[0027] Fig. 10B . FITC intensity and the percentage of FITC-positive neurons were quantified from the images.
[0028] Fig.11 . Neurological function of rats with transient focal cerebral ischemia model after administration of samples. Arrows indicate the time of administration. Neurological deficit scores were measured every other day before each injection. Data are expressed as mean ± SEM. (n = 10). *P < 0.05 and **P < 0.01 (Bonferroni multiple comparison test after two-way RM analysis of variance).
[0029] Fig.12.TTC staining of brain tissues of rats sacrificed on day 7.
[0030] Fig.13 Quantified cerebral infarct volume. Data are presented as mean ± SEM (n = 5). *P < 0.05, **P < 0.01. (Ordinary one-way ANOVA followed by Turkey post hoc). DETAILED DESCRIPTION
[0031] It is known that certain molecules can quickly cross the blood-brain barrier and enter brain tissue, such as nicotine, acetylcholine, meperidine, morphine, and cocaine. Choline, acetylcholine and their analogs can cross the blood-brain barrier through multiple pathways, such as choline transporter (ChT) and nicotinic acetylcholine receptor (nAchR). (Lloyd, GK & Wiliams, J Pharmacol Exp Ther 292, 461-467 (2000)) 2-Methacryloyloxyethyl phosphorylcholine (2-Methacryloyloxyethyl phosphorylcholine, MPC) and its polymer, poly (2-Methacryloyloxyethyl phosphorylcholine, PMPC) have structural features similar to choline and acetylcholine, and can interact with choline transporter (ChT) and nicotinic acetylcholine receptor (nAchR). Therefore, similar to the way choline enters brain tissue, 2-methacryloyloxyethyl phosphorylcholine (MPC) and poly-2-methacryloyloxyethyl phosphorylcholine (PMPC) are facilitated to cross the blood-brain barrier and enter the brain tissue through choline transporter (ChT). Similarly, nicotinic acetylcholine receptor (nAchR)-mediated transcytosis transport mechanism also facilitates 2-methacryloyloxyethyl phosphorylcholine (MPC) and poly-2-methacryloyloxyethyl phosphorylcholine (PMPC) to cross the blood-brain barrier.
[0032] Based on the above design principles, a new type of polymer containing choline, acetylcholine and similar groups can cross the blood-brain barrier through a fast pathway and be effectively delivered to the central nervous system. Therefore, two drug delivery systems can be developed using these polymers, cross-blood-brain barrier nanoparticles (BBB-penetrative Nanoparticles) and cross-blood-brain barrier polymer-bioactive agent conjugates (BBB-penetrative polymer-bioactive agent conjugates).
[0033] Protein drugs and gene drugs can be effectively delivered to the central nervous system by coating with a thin shell containing a polymer with a structure similar to choline and acetylcholine. A variety of crosslinking agents can be used to form the polymer shell, such as N, N'-methylenebisacrylamide (BIS), bis[2-(methacryloyloxy)ethyl]phosphate (BMEP), glycerol dimethacrylate (glycerol dimethacrylate, GDMA), polylactide-based blockcopolymers and bisacrylated peptides. In some embodiments, the crosslinking group is degradable. The crosslinking group can be degraded by hydrolysis, tumor-specific proteases or matrix metalloproteinases. Nanoparticles prepared with degradable crosslinking groups can effectively release the encapsulated protein through the degradation of the polymer shell. Therefore, by introducing degradable crosslinking groups, protein drugs can cross the blood-brain barrier and be effectively released in the central nervous system.
[0034] BBB-penetrative polymer-bioactiveagent conjugates can be obtained by conjugating polymers containing choline transporter (ChT) and nicotinic acetylcholine receptor (nAchR) ligands with therapeutic drugs (proteins, genes, etc.). By functionalizing the reaction unit, controlling the molecular weight and chain structure of the polymer, it can be effectively conjugated with protein drugs.
[0035] Polymer Nanoparticles
[0036] The present invention provides a class of polymer nanoparticles, which include a cross-linked polymer matrix, a plurality of bioactive drugs, and a plurality of polymer nanomaterials with functional groups that can increase the permeability of the blood-brain barrier. Specifically, the copolymer includes polymer monomers, and the group associated with each drug monomer is associated with the drug in a non-covalent bonding manner.
[0037] In certain embodiments, the polymer is a class of copolymers, comprising functional monomers and cross-linker monomers coupled to each functional monomer. In certain embodiments, the bioactive drug is not coupled to the polymer. In certain embodiments, the copolymer also comprises a stabilizing monomer. In certain embodiments, the copolymer comprises a drug monomer, and each drug monomer comprises a drug-associated group associated with the drug (non-covalently).
[0038] Definition 2: The present invention provides a type of polymer nanoparticles, which include a cross-linked polymer, a plurality of bioactive drugs covalently coupled to the polymer, and a plurality of functional groups coupled to the polymer for increasing the permeability of the blood-brain barrier.
[0039] In certain embodiments, copolymers include functional monomers and cross-linking agent monomers coupled to each functional monomer. In other embodiments, copolymers include functional monomers, hydrophilic monomers and cross-linking monomers coupled to each hydrophilic monomer. In certain embodiments, polymers include drug monomers and are coupled to bioactive drugs. In other embodiments, copolymers include drug monomers, and each drug monomer includes a drug-associated group associated with a drug (non-covalent). In certain embodiments, copolymers also include stabilizing monomers.
[0040] The selection of drug-associated groups mainly depends on the ability to polymerize with the drug under specific conditions. For example, if the drug surface has negatively charged groups, then drug-associated groups with positive charges (e.g., amino groups that can be protonated in aqueous solution to form ammonium ions) can form complexes with drug monomers under neutral aqueous conditions. Similarly, for a drug with a positively charged group or surface, groups with negative charges (e.g., carboxylicacids, sulfonic acids, and phosphonic acids that can be deprotonated in aqueous solution to form anions) can form complexes with drug monomers under neutral aqueous conditions. For non-polar drugs, hydrophobic drug-associated groups (e.g., hydrophobic alkyl, aryl, and aralkyl groups) can form complexes with drug monomers in aqueous solution.
[0041] Moreover, whether the bioactive drug is inside or on the surface of the nanoparticle, the polymer nanoparticle can be degraded by hydrolysis acid degradation, enzymatic hydrolysis esterase or peptidase enzymatic protease to achieve complete release. More importantly, by selecting and designing an appropriate polymer, specific targeted delivery of bioactive drugs (for example, by conjugating functional groups on polymer nanoparticles) can be achieved.
[0042] In certain embodiments, the polymer nanoparticles have a size of 10nm-20nm, 20-25nm, 25nm-30nm, 30nm-35nm, 35nm-40nm, 40nm-45nm, 45nm-50nm, 50nm-55nm, 55nm-60nm, 60nm-65nm, 70-75nm, 75nm-80nm, 80nm-85nm, 85nm-90nm, 90nm-95nm, 95nm-100nm, or 100nm-110nm. In some embodiments, the polymer nanoparticles have a size of about 10 nm, 11 nm, 12 nm, 13 nm, 14 nm, 15 nm, 16 nm, 17 nm, 18 nm, 19 nm, 20 nm, 21 nm, 22 nm, 23 nm, 24 nm, 25 nm, 26 nm, 27 nm, 28 nm, 29 nm, 30 nm, 31 nm, 32 nm, 33 nm, 34 nm, 35 nm, 36 nm, 37 nm, 38 nm, 39 nm, 40 nm, 41 nm, 42 nm, 43 nm, nm,4nm,45nm,46nm,47nm,48nm,49nm,50nm,51nm,52nm,53nm,54nm,55nm,56nm,57nm,58nm,59nm,60nm,61nm,6 2nm,63nm,64nm,65nm,66nm,67nm,68nm,69nm,70nm,71nm,72nm,73nm,74nm,75nm,76nm,77nm,78nm,79nm,80nm, 81nm,82nm,83nm,84nm,85nm,86nm,87nm,88nm,89nm,90nm,91nm,92nm,93nm,94nm,95nm,96nm,97nm,98nm,99n m,100nm,101nm,102nm,103nm,104nm,105nm,106nm,107nm,108nm,109nm,110nm,111nm,112nm,113nm,114nm,11 In some preferred embodiments, the nanoparticles have a size of about 5-20 nm.
[0043] In certain embodiments, the polymer nanoparticles are cross-linked to a degree of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%.
[0044] In certain embodiments, the topology of the polymer is linear, dendritic, star-shaped, or multi-branched.
[0045] In certain embodiments, the polymer nanoparticles involved have non-targeting and targeting capabilities, high efficiency, and / or low immunogenicity. For example, high efficiency can lead to increased uptake and more direct delivery.
[0046] In certain embodiments, the degradation time of polymer nanoparticles can be designed to be 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month or any combination of time. In certain embodiments, polymer nanoparticles are designed to degrade at any time under physiological pH conditions. In certain embodiments, polymer nanoparticles are designed to degrade at any time after being administered to the subject for treatment. Generally, the degradation rate increases with the increase of the crosslinking percentage, and decreases with the decrease of the crosslinking percentage. In other embodiments, the degradation rate increases with the increase of the crosslinking percentage. Finally, it is possible to obtain desirable degradation characteristics by regulating and controlling a variety of crosslinking percentages. The stability of bioactive drugs can be enhanced by coating or arranging them on the surface of polymer nanoparticles, ensuring that they can circulate in the human body for a long time before reaching the target site. Overall, the delivery strategy of bioactive drugs described can provide significant efficiency, enhanced stability and minimal toxicity.
[0047] Bioactive drugs In certain embodiments, the drug monomer is coupled to the bioactive drug through a bridging group. In certain embodiments, the bridging group is an alkyl chain, a heteroalkyl chain, or an alkenyl chain. In certain embodiments, the bridging group comprises a variety of bridging monomers. In certain embodiments, the bridging monomers are selected from N, N'-methylenebis(acrylamide) (MBAA) and bis[2-(methacryloyloxy)ethyl]phosphate (BMEP).
[0048] In certain embodiments, the bridging group is degradable. In certain embodiments, the degradable bridging group comprises a cleavable ester bond or peptide bond. In certain embodiments, the degradable bridging group comprises a plurality of degradable bridging group monomers. In certain embodiments, the degradable bridging group monomers can be selected from glycerol dimethacrylate, ethylene glycol dimethacrylate and 2,2-bis(aminoethoxy)propane monomers.
[0049] In certain embodiments, the bridging group is degradable by proteases, esterases, acids, plasmin, collagenases, and matrix metalloproteinases.
[0050] In certain embodiments, the bioactive drug may be a small molecule, a protein, a polynucleotide, and an imaging agent. In certain embodiments, the bioactive drug may be selected from proteins, polynucleotides, and imaging agents.
[0051] In certain embodiments, the bioactive agent is a small molecule, such as carmustine, lomustine, everolimus, temozolomide, paclitaxel, docetaxel, pemetrexed cisplatin, carboplatin, doxorubicin, cyclophosphamide, teniposide, mitomycin, irinotecan, vinorelbine, etoposide, ifosfamide, fluorouracil, prednisone, epirubicin, capecitabine, gemcitabine, ixabepilone, eribulin, pemetrexed, erlotinib, gefitinib, afatinib, crizotinib, ceritinib, alectinib, brigatinib, osimertinib, dabrafenib, tremetinib, sorafenib, sunitinib, temsirolimus, pazopanib, axitinib, cabozantinib, lenvatinib, leucovorin, oxaliplatin, irinotecan, regorafenib, trifluridine, tipiracil, cefaclor, cefradine, cefazolin, lincomycin, erythromycin, imipenem / cilastatin, oxacilin, cloxacilin, mecilinam, cefalexin, demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, colistin, teicoplanin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovirdisoproxil, zidovudine, efavirenz, etravirine, nevirapine, rilpivirine, atazanavir, darunavir, fosamprenavir,indinavir, nelfinavir, saquinavir, tipranavir, enfuvirtide, maraviroc, dolutegravir, elvitegravir, raltegravir, docosanol, acyclovir, valaciclovir, famciclovir, penciclovir, tacrine, rivastigmine, donepezil, galantamine, memantine, levodopa, bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine, lisuride, safinamide, selegiline and rasagiline.,
[0052] In certain embodiments, the bioactive drugs may be selected from growth factors, cytokines, antibodies and enzymes. In some embodiments, the bioactive drug can be bone morphogenetic proteins (BMP), epidermal growth factors (EGF), fibroblast growth factors (FGF), glial cell-derived neurotrophic factors (GDNF), interleukins (IL), nerve growth factors (NGF), brain-derived neurotrophic factors (BDNF), neurotrophins (NT), platelet-derived growth factors (PDGF), vascular endothelial growth factors (VEGF) and neuregulins. In some embodiments, the bioactive drug can be bone morphogenetic protein 2 (BMP-2), bone morphogenetic protein 7 (BMP-7), epidermal growth factor, fibroblast growth factor 1 (FGF-1), fibroblast growth factor 2 (FGF-2), fibroblast growth factor 3 (FGF-3), fibroblast growth factor 4 (FGF-4), fibroblast growth factor 5 (FGF-5), fibroblast growth factor 6 (FGF-6), fibroblast growth factor 7 (FGF-7), fibroblast growth factor 8 (FGF-8), fibroblast growth factor 9 (FGF-9), fibroblast growth factor 10 (FGF-10), fibroblast growth factor 11 (FGF-11), fibroblast growth factor 12 (FGF-12), fibroblast growth factor 13 (FGF-13), fibroblast growth factor 14 (FGF-14),成纤维细胞生长因子15(FGF - 15)、成纤维细胞生长因子16(FGF - 16)、成纤维细胞生长因子17(FGF - 17)、成纤维细胞生长因子18(FGF - 18)、成纤维细胞生长因子19(FGF - 19)、成纤维细胞生长因子20(FGF - 20)、成纤维细胞生长因子21(FGF - 21)、成纤维细胞生长因子22(FGF - 22)、成纤维细胞生长因子23(FGF - 23)、胶质细胞源性神经营养因子、神经营养素、白细胞介素1(IL - 1)、白细胞介素2(IL - 2)、白细胞介素3(IL - 3)、白细胞介素4(IL - 4)、白细胞介素5(IL - 5)、白细胞介素6(IL - 6)、白细胞介素7(IL - 7)、神经生长因子、脑源性神经营养因子、神经营养因子 - 3(NT - 3)、神经营养因子4(NT - 4)、血小板源性生长因子、血管内皮生长因子、神经调节蛋白(NRG1)、神经调节蛋白(NRG2)、神经调节蛋白(NRG3)和神经调节蛋白(NRG4)。
[0053] In some embodiments, the bioactive drug may be selected from Afutuzumab, 3F8, 8H9, Adecatumumab Abituzumab, ado-trastuzumab emtansine, Altumomab pentetate, Atezolizumab Glembatumumab vedotin, Margetuximab, Sacituzumab govitecan, Trastuzumab emtansine, Lorvotuzumab mertansine, Anetumab ravtansine, Ascrinvacumab, Avelumab, Azintuxizumab vedotin, bevacizumab, bevacizumab-awb, BCD-10, Belantamab mafodotin, Bectumomab, Belimumab, Bemarituzumab, Brontictuzumab, Brentuximab vedotin, Cantuzumab ravtansine, Carotuximab, Cabiralizumab, cBR96-doxorubicin immunoconjugate, Camidanlumab tesirine, Cemiplimab, cetuximab, Cetrelimab, Cibisatamab, Citatuzumabogatox, Cixutumumab, Codrituzumab, Cofetuzumab pelidotin, Coltuximab Conatumumab Tetraxetane, Dinutuximab, Dostarlimab, Drozitumab, DS-8201, Durvalumab, Dusigitumab, Duvortuxizumab, Ecromeximab, Eculizumab, Edrecolomab, Elgemtumab, Elotuzumab,Emactuzumab, Emibetuzumab, Enapotamab vedotin, Enavatuzumab, Enfortumab vedotin, Enoblituzumab, Epratuzumab, Ertumaxomab, Etaracizumab, Farletuzumab, FBTA05, Ficlatuzumab, Figumumab, Flanvotumab, Flotetuzumab, Fresolimumab, Futuxim ab, Galiximab, Gancotamab, Ganitumab, Gatipotuzumab, Gemtuzumabozogamicin, Girentuximab, Glembatumabvedotin, IBI308, Ibritumomabtiuxetan, Icrucumab, Igovomab, Iladatuzumab vedotin, IVIAB362, Imalumab, Imgatuzumab, Indatuximab ravtansine, Indusatumab vedotin, Inebilizumab, Intetumab, Inotuzumab ozogamicin, Ipilimumab, Iratumumab, Isatuximab, Stratuzumab, Labetuzumab vedotin, Lenzilumab, Lexatumab, Lifastuzumab vedotin, Loncastuximab tesirine, Losatuxizumabvedotin, Lilotomab satetraxetan, Lintuzumab, Lirilumab, Lorvotuzumabmertansine, Lucatumumab, Lumiliximab, Lumretuzumab, MABpl, Mapatumumab, Margetuximab, Matuzumab, Milatuzumab, Mirvetuximab soravtansine, Mitumomab, Modotuximab, Mogamulizumab, Monalizumab, Mosunetuzumab, Moxetumomabpasudotox, Nacolomab tafenatox,Naptumomab estafenatox,Narnatumab,Navicixizumab,Naxitamab,Necitumumab,Nesvacumab,Nimotuzumab,Nivolumab,Nofetumomab merpentan,Obinutuzumab,Ocaratuzumab,Ofatumumab,Olaratumab,Oleclumab,Omburtamab,Onartuzumab,Ontuxizumab,Oportuzumab monatox,Oregovomab,Otertuzumab,Pascolizumab,Pasotuxizumab,Pateclizumab,Patritumab,PDR01,Pembrolizumab,Pemtumomab,Pertuzumab,Pidilizumab,Pinatuzumab vedotin,Pintumomab,Polatuzumab vedotin,Pritumumab,Racotumomab,Radretumab,Ramucirumab,Relatlimab,Rilotumumab,Rituximab,Robatumumab,Rosmantuzumab,Rovalpituzumabtesirine,Sacituzumab govitecan,Samalizumab,Samrotamab vedotin,Satumomabpendetide,Seribantumab,Cibrotuzumab,SGN-CD19A,Siltuximab,Sirtratumab vedotin,Sofituzumab vedotin,Solitomab,Spartalizumab,Tabulumab,Tacatuzumab tetraxetan,Taplitumomab paptox,Tarextumab,Tavolimab,Telisotuzumab,Tenatumomab,Tepoditamab,Tetulomab,TGN1412,Tigatuzumab,Timigutuzumab,Tiragotumab,Tislelizumab,Tisotumab vedotin,TNX-650,Tomuzotuximab,Tositumomab,Tovetumab,Trastuzumab,Trastuzumab emtansine,TRBS07,Tremelimumab,Tucotuzumabcelmoleukin,Ublituximab,Ulocuplumab,Urelumab,Utomilumab,Vadastuximabtalirine,Vandortuzumab vedotin,Vantictumab,Vanucizumab,Varlilumab,Veltuzumab,Vesencumab,Volociximab,Vonlerolizumab,Vorsetuzumab mafodotin,Votumumab,XMAB-574,Zalutumumab,Zanolimumab,Zatuximab,Zenocutuzumab,Zolbetuximab,Aducanumab,Bapineuzumab,Crenezumab,Elezanumab,E ptinezumab,Erenumab,Erlizumab,Frenezumab,Fulranumab,Foravirumab,Galcanezumab,Gantenerumab,Gosuranemab,Ibalizumab,Lampalizumab,Larcavixime ab,Ozanezumab,Pamrevlumab,Panitumumab,Pancomab,Placulumab,Ponezumab,Prasinezumab,Porgaviximab,PRO140,Ranibizumab,Refanezumab,Rinucumab,Ra fivirumab,RMab,CA237,Satralizumab,Solanezumab,Sonepcizumab,Stamolumab,Suvizumab,Tanezumab,Tefibazumab,Teprotumumab,Trevogrumab,Varisacumab antibodies。,
[0054] In certain embodiments, the bioactive drug can be selected from α-L-iduronidase, iduronate-2-sulfatase, heparin N-sulfatase, glucocerebrosidase, galactocerebrosidase, arylsulfatase A, β-hexosaminidase, recombinant tripeptidyl peptidase 1, α-galactosidase A, tripeptidyl peptidase 1 proenzyme and α-galactosidase enzymes.
[0055] In certain embodiments, the bioactive drug can be selected from gendicine, advexin, oblimersensodium, miR-15a, miR-16-1, miR-143, miR-145, miR-21, members of the let-7 family, miR-142, BIC / miR-15, a member of the miR-17-19b cluster, glutamatedecarboxylate (GAD), netrin (NTN), artermin, aromatic L-amino acid ecarboxylase (ADC), ciliary neurotrophic factor (CNTF), insulin like growth factor 1
[0056] (IGF-1), vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), survival of motor neuron 1 (SMN1), survival of motor neuron 2 (SMN2) and chemokine receptor type 5 (CR5).
[0057] In certain embodiments, the bioactive drug can be selected from DNA with an endosome-escaping protein (eg, phospholipase), RNA with an endosome-escaping protein (eg, phospholipase), a CRISPR / Cas9 complex, a RNA-induced silencing complex (RISC), and a microRNA protein-RNA complex (RNP).
[0058] In certain embodiments, the biologically active drugs can be selected from radio-nucleotides, radio labeled glucose residues, radio labeled antibodies, radio labeled proteins and fluorescent proteins.
[0059] According to the method of the present invention, a new type of radioactive imaging agent can be invented for nuclear medicine experts to use for tissue imaging in mammals. Any mammal tumor can be imaged using the imaging agent described in the present invention. The image is generated by the different spatial distribution of the imaging agent, and this spatial difference comes from the accumulation of the imaging agent in the tissues and organs in the mammal. The spatial distribution of the imaging agent in the mammal, organ or tissue can be measured by a variety of instruments, for example, PET or single photon computed tomography (SPECT) imaging, etc.
[0060] Targeted delivery
[0061] The targeting group of the present invention can be used to target or guide nanoparticles or polymer bioactive drug conjugates to specific sites (e.g., cell types and disease tissues) or interactions (e.g., specific binding). It is particularly noted that polymer nanoparticles or polymer bioactive drug conjugates can be used to target the brain and central nervous system. In certain embodiments, polymer nanoparticles or polymer bioactive drug conjugates containing targeting groups can be more effectively delivered to specific sites (e.g., ischemic tissues) compared to nanoparticles or polymer bioactive drug conjugates that do not contain targeting groups.
[0062] In certain embodiments, bioactive drugs can be effectively delivered to specific sites in vivo using targeting groups. In certain embodiments, optimizing the targeting groups coupled to the surface of nanoparticles can achieve targeted delivery of bioactive drugs.
[0063] In certain embodiments, the conjugation can prevent the targeting group from dissociating from the polymer nanoparticle.
[0064] In certain embodiments, the present invention can achieve efficient, low-toxicity delivery of bioactive drugs via non-targeted and targeted polymer nanoparticles for in vitro testing and in vivo targeting of specific tissues and organs via intravenous injection.
[0065] In certain embodiments, the polymer nanoparticles may include a plurality of targeting groups. In certain embodiments, the targeting groups are distributed on the surface of the polymer nanoparticles. In certain embodiments, the targeting groups are covalently coupled to the nanoparticles.
[0066] In certain embodiments, the polymer in the polymer-bioactive drug conjugate may contain multiple targeting groups. In certain embodiments, the targeting group is covalently coupled to the polymer.
[0067] In certain embodiments, the targeting functional group can be a small molecule, such as folate and arginylglycylaspartic acid (RGD).
[0068] In certain embodiments, the targeted functional proteins are transferins.
[0069] In certain embodiments, the targeted functional protein can be selected from anti-VEGFR antibody, anti-CD20 antibody and anti-ERB2 antibody.
[0070] In certain embodiments, the targeted functional protein can be selected from antigen binding fragment (Fab), single-chain variable fragment (ScFv) and disulfide-stabilized variable antibody fragment (ds-Fv).
[0071] Polymer-bioactive drug conjugates
[0072] Definition, the present invention provides a polymer bioactive drug conjugate, which comprises a bioactive drug covalently coupled to a plurality of polymers, and a plurality of functional groups covalently coupled to the polymers. In certain embodiments, each polymer comprises a copolymer of a transport functional monomer coupled to a transport functional group and a drug monomer coupled to a bioactive drug.
[0073] In certain embodiments, the polymer comprises a plurality of monomers, which may be selected from 2-methacryloyloxyethyl phosphorylcholine (MPC), N-(3-aminopropyl)methacrylamide (APm), trimethyl(2-prop-2-enoyloxyethyl)azanium, methacrylatoethyl trimethyl amonium,
[0074] [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, carboxybetainemethacrylate,
[0075] Acrylamide, poly(ethylene glycol) methylether acrylate, vinylpyridine and carboxybetaine acrylamide monomers. In certain embodiments, the polymer comprises a plurality of individual monomers including 2-methacryloyloxyethyl phosphorylcholine (MPC), N-(3-aminopropyl)methacrylamide (APm), trimethyl(2-prop-2-enoyloxyethyl)azanium, methacrylatoethyltrimethyl amonium, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, carboxybetainemethacrylate, and carboxybetaineacrylamide monomers. In certain embodiments, the polymer comprises a plurality of independent monomers of 2-methacryloyloxyethyl phosphorylcholine (MPC) and a plurality of monomers of N-(3-aminopropyl)methacrylamide (APm).
[0076] In some embodiments, the bioactive drug can be a growth factor, a cytokine, an antibody, an enzyme, a gene, a gene protein complex and an imaging agent. In some embodiments, the bioactive drug can be selected from bone morphogenetic protein (BMP), epidermal growth factor (EGF), fibroblast growth factor (FGF), glialcel-derived neurotrophic factor (GDNF), interleukin (IL), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin (NT), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and neuregulin. In certain embodiments, the bioactive drugs can be selected from bone morphogenetic protein 2 (BMP-2), bone morphogenetic protein 7 (BMP-7), epidermal growth factor, fibroblast growth factor 1 (FGF-1), fibroblast growth factor 2 (FGF-2), fibroblast growth factor 3 (FGF-3), fibroblast growth factor 4 (FGF-4), fibroblast growth factor 5 (FGF-5), fibroblast growth factor 6 (FGF-6), fibroblast growth factor 7 (FGF-7), fibroblast growth factor 8 (FGF-8), fibroblast growth factor 9 (FGF-9), fibroblast growth factor 10 (FGF-10), fibroblast growth factor 11 (FGF-11), fibroblast growth factor 12 (FGF-12), fibroblast growth factor 13 (FGF-13), fibroblast growth factor 14(FGF-14),成纤维细胞生长因子15(FGF - 15)、成纤维细胞生长因子16(FGF - 16)、成纤维细胞生长因子17(FGF - 17)、成纤维细胞生长因子18(FGF - 18)、成纤维细胞生长因子19(FGF - 19)、成纤维细胞生长因子20(FGF - 20)、成纤维细胞生长因子21(FGF - 21)、成纤维细胞生长因子22(FGF - 22)、成纤维细胞生长因子23(FGF - 23)、胶质细胞源性神经营养因子、神经营养素、白细胞介素1(IL - 1)、白细胞介素2(IL - 2)、白细胞介素3(IL - 3)、白细胞介素4(IL - 4)、白细胞介素5(IL - 5)、白细胞介素6(IL - 6)、白细胞介素7(IL - 7)、神经生长因子、脑源性神经营养因子、神经营养因子 - 3(NT - 3)、神经营养因子4(NT - 4)、血小板衍生生长因子、血管内皮生长因子、神经调节蛋白1(NRG1)、神经调节蛋白2(NRG2)、神经调节蛋白3(NRG3)和神经调节蛋白4(NRG4)。
[0077] In some embodiments, the bioactive drug may be selected from Afutuzumab, 3F8, 8H9, Adecatumumab Abituzumab, ado-trastuzumab emtansine, Altumomab pentetate, Atezolizumab Glembatumumab vedotin, Margetuximab, Sacituzumab govitecan, Trastuzumab emtansine, Lorvotuzumab mertansine, Anetumab ravtansine, Ascrinvacumab, Avelumab, Azintuxizumab vedotin, bevacizumab, bevacizumab-awb, BCD-10, Belantamab mafodotin, Bectumomab, Belimumab, Bemarituzumab, Brontictuzumab, Brentuximab vedotin, Cantuzumab ravtansine, Carotuximab, Cabiralizumab, cBR96-doxorubicin immunoconjugate, Camidanlumab tesirine, Cemiplimab, cetuximab, Cetrelimab, Cibisatamab, Citatuzumabogatox, Cixutumumab, Codrituzumab, Cofetuzumab
[0078] pelidotin, Coltuximabravtansine, Conatumumab, Cusatuzumab, Depatuxizumabmaf odotin,
[0079] Dacetuzumab, Dalotuzumab, Detumomab, Daratumumab, Demcizumab, Derlotuximab
[0080] biotin,Denintuzumabmafodotin,Emapalumab,Bivatuzumabmertansine,Carlumab,Clivatuzumabtetraxetan,Dinutuximab,Dostarlimab,Drozitumab,DS-8201,Durvalu mab,
[0081] Dusigitumab, Duvortuxizumab, Ecromeximab, Eculizumab, Edrecolomab, Elgemtum ab,
[0082] Elotuzumab,Emactuzumab,Emibetuzumab,Enapotamabvedotin,Enavatuzumab,
[0083] Enfortumabvedotin, Enoblituzumab, Ensituximab, Epratuzumab, Ertumaxomab,
[0084] Etaracizumab,Farletuzumab,FBTA05,Ficlatuzumab,Figitumumab,Flanvotumab,
[0085] Flotetuzumab, Fresolimumab, Futuximab, Galiximab, Gancotamab, Ganitumab, Gatipotuzumab, Gemtuzumabozogamicin, Girentuximab, Glembatumumabvedotin, IBI308, Ibritumumabtiuxetan, IC rucumab, Igovomab, Iladatuzumabvedotin, IMAB362, Imalumab, Imgatuzumab, Indatuximabravtansine, Indusatumabvedotin, Inebilizumab, Intetumab, Inotuzumabozogamicin, Ipilimumab, Ir atumumab, Isatuximab, Stratumab, Labetuzumab, Lacnotuzumab, Ladiratuzumabvedotin, Lenzilumab, Lexatumab, Lifastuzumabvedotin, Loncastuximabtesirine, Losatuzumabvedotin, Li lotomabsatetraxetan, Lintuzumab, Lirilumab, Lorvotuzumabmertansine, Lucatumab, Lumiliximab, Lumretuzumab, MABp1, Mapatumumab, Margetuximab, Matuzumab, Milatuzumab, Mirvetuximab soravtansine, Mitumomab, Modotuximab, Mogamulizumab, Monalizumab, Mosunetuzumab, Moxetumabpasudotox, Nacolomabtafenatox,
[0086] Naptumumab estafenatox, narnatumab, navicizumab, naxitamab,
[0087] Necitumumab, Nesvacumab, Nimotuzumab, Nivolumab,
[0088] Nofetumomabmerpentan,Obinutuzumab,Ocaratuzumab,Ofatumumab,
[0089] They are aratumab,Oleclumab,Omburtamab,Onartuzumab,Ontuxizumab,
[0090] Oportuzumabmonatox,Oregovomab,Otlertuzumab,Pascolizumab,
[0091] Pasotuxizumab,Pateclizumab,Patritumab,PDR01,Pembrolizumab,
[0092] Pemtumomab,Pertuzumab,Pidilizumab,Pinatuzumabvedotin,Pintumomab,
[0093] Polatuzumabvedotin,Pritumumab,Racotumomab,Radretumab,Ramucirumab,
[0094] Relatlimab,Rilotumumab,Rituximab,Robatumumab,Rosmantuzumab,
[0095] Rovalpituzumabtesirine,Sacituzumabgovitecan,Samalizumab,
[0096] Samrotamabvedotin,Satumomabpendetide,Seribantumab,Sibrotuzumab,
[0097] SGN-CD19A,Siltuximab,Sirtratumabvedotin,Sofituzumabvedotin,Solitomab,
[0098] Spartalizumab,Tabalumab,Tacatuzumabtetraxetan,Taplitumomabpaptox,
[0099] Tarextumab, Tavolimab, Telisotuzumabvedotin, Tenatumomab, Tepoditamab,
[0100] Tetulomab,TGN1412,Tigatuzumab,Timigutuzumab,Tiragotumab,Tislelizumab,
[0101] Tisotumabvedotin,'TNX-650,Tomuzotuximab,Tositumomab,Tovetumab,
[0102] Trastuzumab, Trastuzumab emtansine, TRBS07, Tremelimumab,
[0103] Tucotuzumabcelmoleukin,Ublituximab,Ulocuplumab,Urelumab,Utomilumab,
[0104] Vadastuximabtalirine, Vandortuzumab vedotin, Vantictumab, Vanucizumab,
[0105] Varlilumab, Veltuzumab, Vesencumab, Volociximab, Vonlerolizumab,
[0106] Vorsetuzumab mafodotin, Votumumab, XMAB-574, Zalutumumab,
[0107] Zanolimumab,Zatuximab,Zenocutuzumab,Zolbetuximab,Aducanumab,Bapineuzumab,Crenezumab,Elezanumab,Eptinezumab,Erenumab,Erlizumab,Fremanezumab,Fulranumab,Foravirumab,Galcanezumab,Gantenerumab,Gosuranemab,Ibalizumab,Lampalizumab,Larcaviximab,Ozanezumab,Pamrevl umab,Panitumumab,Pancomab,Placulumab,Ponezumab,Prasinezumab,Porgaviximab,PRO140,Ranibizumab,Refanezumab,Rinucumab,Rafivirumab,R mab, SA237, Satralizumab, Solanezumab, Sonepcizumab, Stamulumab, Suvizumab, Tanezumab, Tefibazumab, Teprotumumab, Trevogrumab, Varisacumab.
[0108] In certain embodiments, the biologically active drug can be selected from α-L-iduronidase, iduronate-2-sulfatase, heparin N-sulfatase, glucocerebrosidase, galactocerebrosidase, arylsulfatase A, β-hexosaminidase, recombinant tripeptidyl peptidase 1, α-galactosidase A, tripeptidyl peptidase 1 proenzyme and α-glucosidase.
[0109] In certain embodiments, the bioactive drug can be selected from gendicine, advexin, oblimersensodium, miR-15a, miR-16-1, miR-143, miR-145, miR-21, a member of the let-7 family, miR-142, BIC / miR-155, a member of the miR-17-19b cluster, glutamatedecarboxylate (GAD), netrin (NTN), artermin, aromatic L-aminoacid decarboxylase (AADC), ciliary neurotrophic factor (CNTF), insulin like growth factor 1 (IGF-1), vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), survival of motor neuron 1 (SMN1), survival of motor neuron 2 (SMN2), and chemokine receptor type 5 (CCR5).
[0110] In certain embodiments, the bioactive drug can be selected from DNA with an endosome-escaping protein (eg, phospholipase), RNA with an endosome-escaping protein (eg, phospholipase), CRISPR / Cas9 complex, RNA-induced silencing complex (RISC) and micro RNA protein-RNA complex (RNP).
[0111] In some embodiments, the bioactive drug may be a fluorescent protein.
[0112] Enhanced biofilm penetration
[0113] The polymer nanoparticles and polymer bioactive drug conjugates of the present invention contain multiple transport functional groups that can enhance the ability of biological membrane penetration. In certain embodiments, compared with nanoparticles and conjugates without transport functional groups, the introduction of transport functional groups can increase the ability of nanoparticles or conjugates to pass through the blood-brain barrier.
[0114] Typically, the transport functional group (eg, Formula I, V, or VI) is coupled to a monomer and then coupled to a copolymer. Alternatively, the transport functional group itself is a monomer or is directly coupled to a copolymer (eg, compound Formula II, III, IV, or VI). In certain embodiments, the transport functional group can be independently selected as a neurotransmitter, an opioid, and a central nervous system stimulant. In certain embodiments, the transport functional group can be covalently coupled to a polymer. In other embodiments, the transport functional group can be attached to a polymer in a non-covalent manner (by hydrogen bonding or charge-charge interaction).
[0115] In certain embodiments, the transport functional group can be selected from choline, acetylcholine, nicotine, phosphorylcholine, muscarine, cocaine, meperidine, morphine, dopamine and serotonin groups, respectively.
[0116] In certain embodiments, the transport functional group structure can be referred to as follows or a pharmaceutically acceptable salt thereof:
[0117] X1-A-Y1
[0118] I
[0119]
[0120] In the picture
[0121] X1, X2, X3 or X4 is a cationic group, usually containing a nitrogen atom;
[0122] A is a spacer unit;
[0123] Y1 or Y2 is a hydrogen bond acceptor, usually comprising a nitrogen atom or an oxygen atom;
[0124] Represents the chemical bonds connecting the polymer
[0125] In certain embodiments, the cationic group has at least one positive charge or two positive charges.
[0126] In certain embodiments, the hydrogen bond acceptor has at least one hydrogen bond acceptor, at least two hydrogen bond acceptors, or at least three hydrogen bond acceptors.
[0127] In certain embodiments, the transport functional group structure is represented by structural formula I or a pharmaceutically acceptable salt thereof.
[0128] X1-A-Y1
[0129] I
[0130] In the picture
[0131] X1 is amino, guanidino, hydrazino, diazonium, phosphonium, sulfonium, or heterocyclyl;
[0132] A is alkyl, aryl, cycloalkyl or heteroaryl;
[0133] Y1 is amido, amidino, oxygen, alkyloxy, azo, carboxyl, alkenyl, ester, keto, phosphate, sulfoxide, sulfone, sulfonamido, heteroaryl or heterocyclyl.
[0134] In certain embodiments, the transport functional group structure is represented by structural formula II or a pharmaceutically acceptable salt thereof.
[0135]
[0136] In the picture
[0137] X2 is amino, guanidino, hydrazino, phosphonium, sulfonium, or heterocyclyl;
[0138] A is alkyl, aryl, cycloalkyl or heteroaryl;
[0139] Y1 is amido, amidino, oxygen, alkyloxy, azo, carboxyl, alkenyl, ester, keto, phosphate, sulfoxide, sulfone, sulfonamido, heteroaryl or heterocyclyl.
[0140] In certain embodiments, Y1 is an alkenyl group. In certain embodiments, Y1 is a structure shown in the figure In the figure, R1 is hydrogen, alkyl, aryl, cycloalkyl or heteroaryl.
[0141] In certain embodiments, the transport functional group structure is represented by structural formula III or a pharmaceutically acceptable salt thereof.
[0142]
[0143] In the picture
[0144] X1 is amino, guanidino, hydrazino, diazonium, phosphonium, sulfonium, or heterocyclyl;
[0145] A is alkyl, aryl, cycloalkyl or heteroaryl;
[0146] Y2 is amido, amidino, oxygen, alkyloxy, azo, carboxyl, alkenyl, ester, ketone, phosphate, sulfoxide, sulfone, sulfonamido, heteroaryl or heterocyclyl.
[0147] In the optimized structural formulas I, II, and III of certain embodiments, A is an alkyl group. In the most preferred structural formula, A is a C1-C10 alkyl group.
[0148] In certain embodiments, the transport functional group structure is represented by structural formula IV or a pharmaceutically acceptable salt thereof.
[0149]
[0150] In the picture
[0151] X2 is amino, guanidino, hydrazino, phosphonium, sulfonium, or heterocyclyl;
[0152] A is alkyl, aryl, cycloalkyl or heteroaryl;
[0153] Y2 is amido, amidino, oxygen, alkyloxy, azo, carboxyl, alkenyl, ester, ketone, phosphate, sulfoxide, sulfone, sulfonamido, heteroaryl or heterocyclyl.
[0154] In certain embodiments, the transport functional group structure is represented by structural formula V or a pharmaceutically acceptable salt thereof.
[0155]
[0156] In the picture
[0157] X3 is amino, guanidino, hydrazino, diazonium, phosphonium, sulfonium, or heterocyclyl.
[0158] In certain embodiments, the transport functional group structure is represented by structural formula V or a pharmaceutically acceptable salt thereof.
[0159]
[0160] In the picture
[0161] X4 is amino, guanidino, hydrazino, phosphonium, sulfonium, or heterocyclyl.
[0162] In certain embodiments of the preferred structural formulas I, II, III, IV, V and VI, the amino group is present in the form of a tertiary amine salt or a quaternary amine salt.
[0163] In certain embodiments, inclusion of a transport group can enhance the permeability of biological membranes compared to nanoparticles or conjugates lacking the transport functional group.
[0164] In certain embodiments, compared to nanoparticles and conjugates lacking water-philic groups, the polymer nanoparticles or polymer bioactive drug conjugates described in the present invention introduce at least one hydrophilic group to improve the permeability of the nanoparticles or conjugates to biological membranes and the plasma stability.
[0165] Generally, introducing hydrophilic groups can improve its plasma stability and increase the permeability of its biofilm by reducing the adhesion of organic matter and biomacromolecules in the blood. In certain embodiments, hydrophilic groups can be hydrophilic small molecules (monomers), oligomers or polymers, which are present on the nanoparticles or conjugate surfaces of preparation. In other embodiments, hydrophilic groups are attached to the nanoparticles (for example, hydrophilic groups are coupled to the hydrophilic monomers to prepare copolymers) during the preparation process. In certain embodiments, hydrophilic groups are embedded or embedded in polymers. In certain embodiments, hydrophilic groups are attached to polymers in non-covalent forms such as hydrogen bonds.
[0166] In certain embodiments, the hydrophilic group has at least one hydrogen bond acceptor (eg, nitrogen or oxygen).
[0167] In some embodiments, the hydrophilic group can be an amphiphilic ionic polymer. In some embodiments, the amphiphilic ionic polymer can be polyphosphorylcholine, polysulfobetaine, and polycarboxybetaine.
[0168] In other embodiments, the hydrophilic group may not be an amphiphilic ionic polymer. In certain embodiments, the hydrophilic group may be a neutral polymer. In certain embodiments, the hydrophilic group is polyethylene glycol (poly(ethylene glycol), poly(vinylpyridine), poly(2-hydroxyethylmethacrylate), poly-sacharide. In certain embodiments, the hydrophilic group may be poly(oligoethylene glycol) poly(methacrylate), poly(acrylate), polyamide poly(amide), polypeptide poly(peptoid), polyoxazoline poly(oxazoline), poly(hydroxylethylacrylate), poly(ethylethylenephosphate).
[0169] In certain embodiments, the molar ratio of hydrophilic groups to transport functional groups is about 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 10: 1, and 20: 1. In certain embodiments, the ratio of hydrophilic groups to transport functional groups is about 1: 1. In certain embodiments, the ratio of hydrophilic groups to transport functional groups is about 20: 1.
[0170] In certain embodiments, the amount of hydrophilic groups present is such that the amount of hydrophilic groups that can be exposed to a certain number of biomolecules and adsorbed on the surface of polymer nanoparticles and polymer bioactive drug conjugates is no less than 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2% or 1% of the amount that exists alone under the same conditions when the hydrophilic groups are absent.
[0171] Monomers and Cross-linkers Various monomers and cross-linkers can be used to achieve delivery of bioactive drugs (including proteins, small molecules or genes) by in situ polymerization, such as the method described in the present invention and other methods commonly used in the art.
[0172] In certain embodiments, the transport functional monomer can be selected from 2-methacryloyloxyethyl phosphorylcholine (MPC), N-(3-aminopropyl)methacrylamide (APm), quaternized dimethylaminoethyl methacrylate, trimethyl(2-prop-2-enoyloxyethyl)azanium, methacrylatoethyltrimethyl amonium, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, carboxybetaine methacrylate and carboxybetaine acrylamide monomers. In an optimized embodiment, the transport functional group is a methacryloyloxyethyl phosphorylcholine monomer. In certain embodiments, the transport functional group comprises a vinyl pyridine monomer. In certain embodiments, the transport functional group comprises a poly(ethylene glycol) methyl ether acrylate monomer.
[0173] In certain embodiments, the pharmaceutical agent monomer is a methacrylate, which can be covalently coupled to one or more biologically active drugs, for example, an ester group can be formed through a hydroxyl group contained in the biologically active drug itself, or a lipid group can be covalently coupled to one or more biologically active drugs through a hydroxyl group on a bridging group. Representative examples include methacrylates in polyethylene glycol, methacrylates in small molecules (e.g., methacrylates in everolimus), methacrylates in antibodies, and methacrylates in peptide proteins containing hydroxyl moieties, such as serine and threonine.
[0174] In certain embodiments, the pharmaceutical agent monomer is methacrylamide, which can be covalently coupled to one or more biologically active drugs, for example, it can be formed by the amino group contained in the biologically active drug itself, or by covalently coupling the amino group on the bridging group with one or more biologically active drugs. Representative examples include methacrylamide in small molecules (e.g., methacrylamide in fluoxetine), methacrylamide in antibodies, and peptide proteins containing amino groups, such as lysine. In certain embodiments, the pharmaceutical agent monomer can be selected from ethyl acrylate, methacrylamide, and N-(3-aminopropyl) methacrylamide (APm) monomers, respectively.
[0175] In certain embodiments, the crosslinking agent monomer can be selected from N, N'-methylenebisacrylamide (BIS), bis[2-(methacryloyloxy)ethyl]phosphate (BMEP), glycerol dimethacrylate (GDMA), polylactide-based block copolymer and bisacrylated peptide. In certain embodiments, the crosslinking agent monomer can be selected from glycerol dimethacrylate (GDMA), polylactide-based block copolymer and bisacrylated peptide. In certain embodiments, the polylactide block copolymer is poly( DL -lactide)-b-Poly(ethyleneglycol)-b-Poly( DL In certain embodiments, the diacrylated peptide is diacrylated VPLGVRTK. In certain embodiments, the diacrylated peptide is diacrylated KNRVK. In certain embodiments, the diacrylated peptide is diacrylated GIPVSLRSGK. In certain embodiments, the diacrylated peptide is diacrylated GVPLSLYSGK. In certain embodiments, the diacrylated peptide is a glomerular protease substrate.
[0176] In certain embodiments, the stabilizing functional monomer is a polyethylene glycol monomer.
[0177] In certain embodiments, the cross-linked monomers can be degraded by acid, base, enzyme, adenosine triphosphate, oxidant, reductant, glucose, hypoxic conditions, visible light, ultraviolet light, infrared light or heat. In certain embodiments, the cross-linked monomers can be degraded by protease, esterase, plasmin, collagenase or matrix metalloproteinase. Some standard degradable cross-linkers and non-degradable cross-linkers are summarized in Table 2 of US Patent US2015 / 0071999.
[0178] Imaging methods
[0179] In certain embodiments, the present invention provides a desired method for imaging the central nervous system, specifically comprising injecting a certain effective dose of polymer nanoparticles or polymer bioactive drugs containing imaging agents into the target to be detected. In certain embodiments, the method can be expanded to include imaging units containing detectable imaging agents.
[0180] Treatment
[0181] In certain embodiments, the present invention can be used to treat diseases or disorders, such as cancer, neurodegenerative diseases, central nervous system disorders, and viral infections.
[0182] In certain embodiments, the range of cancers includes blastoma, glioblastoma, myeloma, central nervous system tumors, tumorangiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, and environmentally induced cancers.
[0183] In certain embodiments, the neurodegenerative disease or central nervous system dysfunction range includes Alzheimer's disease, Parkinson's disease, Dementia with Lewy bodies, Multiple systematrophy, Prion diseases, Motor neuron disease, Huntington's disease, Amyotrophic lateral sclerosis, Ataxia telangiectasia, Pick's disease, Krabe's disease, Kenedy's disease, Primary lateral sclerosis, Cockayne syndrome, Metachromaticleukodystrophy, TaySach's disease, Sandhof's disease, Latein fantile neuronalceroid lipofuscinosis, Pompe's disease, Spinocerebelar ataxia, HIV-asociated neurocognitive disorders, Stroke, Lou Gehrig's disease, Creutzfeldt-Jakobdisease, Spinal cord injury, Cerebral palsy, Multiple sclerosis, Progresivesupranuclear palsy, Pelizaeus-Merzbacher disease, Tabes dorsalis and Spinal muscular atrophy. In certain embodiments, the neurodegenerative disease or central nervous system dysfunction is a symptom of cerebral ischemia. In certain embodiments, viral infections include human immunodeficiency virus (HIV), Rabies virus, Zika virus and Herpes simplex virus (HSV).
[0184] Non-limiting examples of cell proliferation and / or differentiation disorders include cancer, such as carcinoma, blastoma, glioblastoma and sarcoma, metastatic disease or hematopoietic tumor disease, such as leukemia. Metastatic tumors can come from a variety of primary tumor types, including but not limited to prostate, colon, lung, breast and liver. The terms "cancer", "overproliferation" and "neoplastic" used herein refer to cells with autonomous growth ability, that is, abnormal states are manifested by rapid growth. These terms include the following types, cancer growth or change process, metastatic tumor or malignant transformation of cells, tissues or organs, pathological types or infiltration stages. Proliferative diseases also include hematopoietic tumor diseases, including hyperplasia / tumor cells involving hematopoietic primary, such as macula, lymphoid or erythroid system, and precursor cells.
[0185] Injection method
[0186] The pharmaceutical composition included in the present invention can be administered by any appropriate means, not limited to oral or parenteral routes, such as intravenous injection, intramuscular injection, intraperitoneal injection and subcutaneous injection. In certain embodiments, the pharmaceutical composition of the present invention can be administered by intravenous, parenteral infusion or injection. In a preferred embodiment, the pharmaceutical composition of the present invention can be administered by intravenous injection. In other preferred embodiments, polymer nanoparticles and polymer bioactive drug conjugates can be administered locally, such as eye drops.
[0187] The administration "subject" defined in the present invention is not limited to humans (males or females of any age group, such as children, including infants, children and adolescents; adult subjects, including young, middle-aged and elderly) or primates (such as cynomolgus monkeys, macaques) or mammals, including commercially relevant animals, cattle, pigs, horses, sheep, goats, cats, dogs and / or birds, wherein birds include commercially relevant animals, chickens, ducks, geese, pheasants and / or turkeys. The preferred subject is human.
[0188] In certain embodiments, the drug composition can be administered nasally, with a dosage time of once a day, once a week, once every two weeks, or once a month. In certain embodiments, the nanoparticles and drug composition can be administered nasally. The definition "nasal" or "nasal administration" described here mainly refers to the delivery of nanoparticles to the mucous membrane of the subject's nose, so that a certain amount of nanoparticles can be directly absorbed by the nasal tissue. In certain embodiments, polymer nanoparticles and polymer bioactive drug conjugates and combinations comprising the same can be administered systemically.
[0189] Drug ingredients
[0190] The pharmaceutical composition and administration method of the present invention can be customized according to the needs of individual individuals. In certain embodiments, the individual is a mammal, such as a human or a non-human mammal. When administered to an animal, such as a human, the drug combination or nanoparticle or conjugate should preferably include a drug combination of nanoparticles or conjugates of the present invention, and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers generally include aqueous solutions, such as water or saline, and other solutions or media, such as ethylene glycol, glycerol, oil, including olive oil or injectable organic esters. In a preferred embodiment, when the drug combination is used for human administration, especially for invasive routes of administration, such as injection or implantation, the aqueous solution should be non-pyrogenic or sub-pyrogenic. Excipients can be selected for delayed drug release or selective targeting of one or more cells, tissues and organs. The drug combination of the present invention can be made into edible products, such as tablets, capsules (including sprinkle capsules and gelatin capsules), granules, lyophilized agents, powders, solutions, syrups, suppositories, injections, etc.
[0191] The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions or dosage forms which are suitable for use in contact with human and animal tissues within the scope of sound medical judgment and which do not cause excessive toxicity, irritation, allergic response or other problems.
[0192] The term "pharmaceutically acceptable carrier" as used herein refers to a pharmaceutically acceptable material, ingredient or vehicle, such as a liquid or solid filler, diluent, excipient, solution or coating material. Each carrier must be "acceptable" in terms of compatibility with another form of pharmaceutical formulation and not harmful to the patient. The following materials can be used as pharmaceutically acceptable carriers, including (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) astragalus powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as viscose fiber and suppository wax; (9) oils, such as peanut oil, cotton oil, sunflower oil, sesame oil, olive oil, carob oil; (10) Glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol (mannitol), mannan; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer and (21) other types of non-toxic compatible substances used in pharmaceutical preparations.
[0193] The pharmaceutically acceptable carrier may contain a physiologically acceptable agent to improve stability, increase solubility or increase the absorption capacity of the nanoparticle or polymer bioactive drug conjugate of the present invention. The physiologically acceptable agent includes carbohydrates, such as glucose, sucrose or dextran, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers and excipients. The pharmaceutically acceptable carrier, including the selection of physiologically acceptable agents, depends on the mode of administration of the agent. The preparation of the preparation or pharmaceutical combination can be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical combination (preparation) can also be a liposome or other polymer matrix, and the nanoparticle or conjugate is incorporated therein. For example, liposomes or other lipid-composition liposomes are non-toxic, biocompatible, metabolizable carriers, and are easy to prepare and use.
[0194] The pharmaceutical combination (preparation) can be administered by any of a variety of routes of administration, including oral administration (e.g., dissolved in water or non-aqueous solutions or suspensions, tablets, capsules, including sprinkle capsules and gelatin capsules, pills, powders, granular preparations, adhesives) and subcutaneous administration. In certain embodiments, the nanoparticles or conjugates are easily dissolved or suspended in sterile water. For detailed suitable routes of administration and pharmaceutical combinations, please refer to U.S. Patents, US Pat. Nos. 6,10,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, and related references thereto.
[0195] The formulation can be conveniently expressed in unit dosage form and can be prepared by any method known in pharmacy. The dosage of the active ingredient combined with the carrier material to obtain a single dose will be determined according to the target object to be treated and the specific mode of administration. The dosage of the active ingredient combined with the carrier material to obtain a single dose is generally the dosage of the nanoparticle or conjugate to produce a therapeutic effect. In general, the dosage of the active ingredient can range from 1% to 99%, preferably 5% to 70%, and most preferably 10% to 30%.
[0196] The preparation methods of these preparations or pharmaceutical combinations include the steps of combining the nanoparticles and conjugates related to the present invention with a carrier, or optionally with one or more auxiliary raw materials. Generally, the nanoparticles or conjugates of the present invention are uniformly and closely compounded with a liquid carrier or a finely divided solid carrier, or both, to prepare the preparation, and then subjected to a shaping treatment if necessary.
[0197] The oral administration preparations of the present invention can be capsules (sprinkle capsules and gelatin capsules) in various forms, cachets, pills, tablets, lozenges (usually using sucrose, gum arabic or tragacanth), lyophilized preparations, powders, granules, aqueous or non-aqueous solutions and suspensions, oil-in-water or water-in-oil emulsions, elixirs or syrups, bulk lozenges (using inert bases, such as gelatin and glycerin, or sucrose and chrysanthemum) and / or mouthwashes, each of which contains a predetermined amount of the nanoparticles or conjugates of the present invention as active ingredients. The pharmaceutical combination, nanoparticles or conjugates can also be administered in the form of pills, granules or pastes.
[0198] Oral solid dosage forms (capsules (including microcapsules and gel capsules), tablets, pills, dragees, powders, granules, etc.) can be prepared by mixing the active ingredient with one or more pharmaceutically acceptable carriers, such as citric acid or sodium tripolyphosphate, and / or any of the following substances: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid; (2) binders, such as carboxymethyl cellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or gum arabic; (3) humectants, such as Glycerol; (4) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, silicates and sodium carbonate; (5) retarders, such as paraffin oil; (6) absorption enhancers, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and glyceryl stearate; (8) absorbents, such as kaolin and bentonite; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof; (10) complexing agents, such as modified and unmodified cyclodextrins; (11) coloring agents. In the case of capsules (including micropellet capsules and gel capsules), tablets, and pills, the pharmaceutical composition may also contain a buffer. Similar solid compositions may also use soft and hard-filled gelatin capsules, for example, using lactose, milk sugar or high molecular weight glycolipids.
[0199] Tablets can be prepared by compression or molding, and one or more auxiliary ingredients may be selected. Compressed tablets may use binders (e.g., gelatin or hydroxypropyl methylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate, cross-linked sodium carboxymethyl cellulose), surfactants or dispersants. For the preparation of molded tablets suitable for machine molds, the powdered nanoparticles or conjugates can be wetted by mixing with an inert liquid diluent.
[0200] Tablets and other solid preparation forms containing the drug ingredients, such as dragees, capsules (including micro-pellet capsules and gel capsules), pills, granules, etc., can be obtained by coating or shell layers, such as enteric coatings or other known coating preparations. They can also obtain slow or controlled release of active ingredients by different ratios, such as mixing hydroxypropyl methylcellulose in different proportions to obtain ideal release characteristics. Similarly, they can be mixed with other polymer matrices, liposomes and / or microspheres in different ratios to obtain ideal release characteristics. They can be sterilized in a variety of ways, such as filtering through a filter that can retain bacteria, or through sterile water containing sterilizing ingredients, or quickly injecting sterilizing agents before use. These medicaments can also be selected to contain light-shielding agents, and can be selectively delayed release of active ingredients alone or preferentially in certain parts of the gastrointestinal tract. Examples of embedded drug ingredients that can be used are polymer matrices and waxes. The active ingredient can also be present in microcapsule form, if appropriate, it can be one or more of the above-mentioned excipients.
[0201] Liquid preparations for oral administration include pharmaceutically acceptable emulsions, lyophilized preparations, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid preparation may include commonly used inert diluents, such as water or other solvents, cyclodextrins and their derivatives, solubilizers and demulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oil (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuranol, polyethylene glycol, sorbitan fatty acid esters and mixtures thereof.
[0202] Besides inert diluents, oral dosage forms may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents, coloring agents, perfumes and preservatives.
[0203] In addition to nanoparticles or conjugates, the suspension may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, gelatin and acacia, and mixtures thereof.
[0204] Formulations that can be administered topically or transdermally include powders, sprays, ointments, pastes, creams, emulsions, gels, solutions, patches and inhalants. The active nanoparticles or conjugates can be mixed with a pharmaceutically acceptable carrier under sterile conditions and can be mixed with any desired preservatives, buffers or propellants.
[0205] In addition to the active nanoparticles and conjugates, ointments, pastes, creams and gels may contain excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, acacia, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0206] The term "parenteral administration" as used herein refers to other modes of administration other than enteral and topical administration, usually by injection, including but not limited to intravenous, intramuscular, intercostal, interthecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intravertebral, intrasternal injection and infusion. Pharmaceutical ingredients suitable for parenteral administration include one or more nanoparticles and conjugates and one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, sterile powders, and their composition may be similar to that of a sterile injection or dispersion. The pharmaceutical ingredients may contain sterilizing agents, buffers, bacteriostats, solutes that allow them to be compatible with the blood of the intended subject, suspending agents, thickeners, or formulated into isotonic solutions.
[0207] Aqueous and non-aqueous solutions applicable to pharmaceutical ingredients described herein include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.), and applicable mixtures thereof, vegetable oils, such as olive oil, organic esters for injection, such as ethyl oleate. The fluidity of the medicament can be maintained in a variety of ways, for example, by using coating materials such as lecithin, by maintaining a suitable particle size under dispersion conditions, by using a surfactant. These pharmaceutical ingredients can also include adjuvants such as preservatives, wetting agents, emulsifiers, and dispersants. The effect of preventing microorganisms can be ensured by adding various antibacterial and antifungal agents (such as parabens, chlorobutanol, phenol sorbic acid, etc.). At the same time, isotonic agents, such as sugar, sodium chloride, etc., may also need to be added to the pharmaceutical ingredients. In addition, the absorption of injectable drugs can be extended by coating agents that can delay absorption (such as aluminum monostearate and gelatin).
[0208] In some cases, in order to prolong the action of the drug, it is desirable to slow down the absorption of the subcutaneous or intramuscular injection of the drug. Therefore, this can be achieved by a suspension of a crystalline or amorphous material with poor water solubility. The absorption rate of the drug depends on the dissolution rate, which depends on the size and crystalline form of the crystals. Alternatively, delayed absorption of the parenteral drug component can be achieved by dissolving or suspending the drug in an oily carrier.
[0209] For the method of the present invention, the active substance is present in an amount of 0.1% to 99.5% (optimally 0.5% to 90%) of the pharmaceutical composition containing a pharmaceutically acceptable carrier.
[0210] The method can also be implemented by rechargeable or degradable devices. In recent years, a variety of sustained-release polymer devices have been reported for the controlled delivery of drugs such as protein biopharmaceuticals and successfully tested in vivo. A large number of biocompatible polymers (such as hydrogels), including degradable and non-degradable polymers, can be made into implants for sustained release of nanoparticles or conjugates at specific targets.
[0211] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain a dose of the active ingredient which is effective to achieve the desired therapeutic effect for a particular patient, composition, and mode of administration, without being pharmaceutically toxic to the patient.
[0212] The selected dosage level depends on a variety of factors, including the activity of the specific nanoparticle or conjugate used or its mixture or lipid, salt or amide, the mode of administration, the time of administration, the excretion rate of the specific nanoparticle or conjugate used, the duration of other drugs, compounds or materials used in combination with the nanoparticle or conjugate used, age, sex, weight, condition, general health and medical history, and other common medical factors. A physician or veterinarian with ordinary technical skills in the field can easily determine and prescribe the effective therapeutic dose of the required drug component. For example, the physician or veterinarian can start with a starting dose of the drug component, that is, a dose of the nanoparticle or conjugate that is lower than the dose required to achieve the therapeutic efficiency, and gradually increase the dose until the desired therapeutic efficiency is achieved. The concentration of the nanoparticle or conjugate that can achieve the desired therapeutic effect is determined by the "therapeutically effective dose". In general, the effective concentration of the nanoparticle or conjugate depends on the subject's weight, sex, age and medical history. Other factors may also affect the effective dose, including but not limited to, the severity of the patient's condition, the disease being treated, the anti-disease properties of the nanoparticles or conjugates, and other therapeutic drugs that can be used in combination with the nanoparticles or conjugates of the present invention if necessary. A larger total dose of the drug component can be delivered by multiple administrations. Determining effectiveness and dosage can refer to the reported methods (Iselbacher et al. (1996) Harison's Principles of Internal Medicine 13 ed., 1814-1882)
[0213] Generally, the daily dosage of the nanoparticles or conjugates suitable for the pharmaceutical composition and method of the present invention is the minimum dosage of the nanoparticles or conjugates that produces a therapeutic effect. The effective dosage depends on the above-mentioned influencing factors.
[0214] If desired, the effective daily dose of the nanoparticle or conjugate can be administered once, twice, three times, four times, five times, six times or more throughout the day, or in an optional single dose form. In certain embodiments, the nanoparticle or conjugate of the present invention can be administered twice or three times a day. In a preferred embodiment, the nanoparticle or conjugate is administered once a day.
[0215] Patients receiving the drug treatment of the present invention can be any animal in need, including primates, especially humans, and other mammals, such as horses, cattle, pigs, sheep, cats and dogs, poultry, and pets. In certain embodiments, the nanoparticles or conjugates of the present invention can be used alone or co-administered with other types of therapeutic drugs.
[0216] The present invention includes pharmaceutically acceptable salts of the nanoparticles or conjugates described in the pharmaceutical compositions and methods. In certain embodiments, the salts described herein include, but are not limited to, alkyl, dialkyl, trialkyl or tetraalkylamine salts. In certain embodiments, the salts described herein include, but are not limited to, L-arginine, benzylamine, benzathine, betaine, calcium hydroxide, choline, dealcoholization, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydrazine, 1H-imidazole, lithium salts, L-lysine, magnesium salts, 4-(2-hydroxyethyl)morpholine, piperazine, potassium salts, 1-(2-hydroxyethyl)pyrrolidine, sodium salts, triethanolamine, tromethamine and zinc salts. In certain embodiments, the salts described herein include, but are not limited to, metal salts containing Na, Ca, K, Mg, Zn and other metals. In certain embodiments, the salts described in the present invention include, but are not limited to, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, 1-ascorbic acid, 1-aspartic acid, benzenesulfonic acid, benzoic acid acid,(+)-camphoric acid,(+)-camphor-10-sulfonicacid,capric acid(decanoic acid),caproic acid(hexanoic acid),caprylic acid(octanoic acid),carbonic acid,cinnamic acid,citric acid,cyclamic acid,dodecylsulfuric acid,ethane-1,2-disulfonic acid,ethanesulfonic acid,formicacid,fumaric acid,galactaric acid,gentisic acid,d-glucoheptonic acid,d-gluconic acid,d-glucuronic acid,glutamic acid,glutaric acid,glycerophosphoric acid,glycolic acid,hippuric acid,hydrobromic acid,hydrochloric acid,isobutyric acid,lactic acid,lactobionic acid,lauric acid,maleic acid,1-malicacid,malonic acid,mandelic acid,methanesulfonic acid,naphthalene-1,5-disulfonic acid,naphthalene-2-sulfonic acid,nicotinic acid,nitric acid,oleicacid,oxalic acid,palmitic acid,pamoic acid,phosphoric acid, proprionic acid, 1-pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, 1-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid and undecylenic acid acid salts.,
[0217] Pharmaceutically acceptable acid salts may also exist in various solvates, such as solutions formed with water, methanol, ethanol, dimethylformamide, etc. Mixtures of such solvates may also be prepared. The source of such solvates may be the solvent of the crystallisate, as well as the inherent solvent used for preparation, crystallization or uncertainty.
[0218] The pharmaceutical composition may also contain wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate and magnesium stearate, coloring agents, sustained-release agents, coating agents, sweeteners, flavoring agents and perfuming agents, preservatives and antioxidants.
[0219] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium sulfate, sodium bisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, etc.; (3) metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.
[0220] Synthesis method
[0221] From one aspect, the present invention discloses a method for preparing polymer nanoparticles, comprising: combining i) a plurality of transport monomers, each transport monomer coupled to at least one transport group; ii) a plurality of cross-linking monomers; iii) a plurality of reagent monomers, each coupled to at least one bioactive agent; iv) a solvent; and initiating copolymerization of the monomers with an initiator. In some embodiments, the combination further comprises combining with a plurality of targeting groups. In some embodiments, the combination further comprises combining with a plurality of stabilizing monomers.
[0222] From another aspect, the present invention discloses a method for preparing polymer nanoparticles, the method comprising: i) combining a plurality of transport monomers, each transport monomer coupled to at least one transport group; ii) a plurality of cross-linking monomers; iii) a plurality of bioactive agents; iv) a solvent; and initiating copolymerization of the monomers with an initiator. In certain embodiments, the bioactive agent is selected from proteins, polynucleotides, and imaging agents. In certain embodiments, the molar ratio of the bioactive agent to the monomer is about 5,000:1 to 12,000. In certain embodiments, the molar ratio of the bioactive agent to the monomer is about 5,000:1. In certain embodiments, the molar ratio of the bioactive agent to the monomer is about 12,000:1. In certain embodiments, the molar ratio of the bioactive agent to the monomer is about 500:1. In certain embodiments, the combination further comprises combining with a plurality of target groups. In certain embodiments, the combination further comprises combining with a plurality of stabilizing monomers. In certain embodiments, the combination further comprises combining with a plurality of hydrophilic groups.
[0223] In another aspect, the present disclosure provides a method for preparing polymer nanoparticles, the method comprising: combining i) a plurality of cross-linking monomers; and ii) a plurality of reagent monomers, each coupled to at least one bioactive agent; iii) a solvent; and initiating copolymerization of the monomers with an initiator. In certain embodiments, the combination further comprises combining with a plurality of transport groups. In certain embodiments, the combination with a plurality of transport groups comprises combining with a plurality of transport monomers, each transport monomer coupled to at least one transport group. In certain embodiments, the combination further comprises combining with a plurality of targeting groups. In certain embodiments, the combination further comprises combining with a plurality of stabilizing monomers.
[0224] On the other hand, the present disclosure provides a method for preparing polymer nanoparticles, the method comprising: combining i) a plurality of monomers, each coupled to at least one transport group; and ii) a plurality of cross-linking monomers; iii) a solvent; and initiating copolymerization of the monomers with an initiator. In certain embodiments, the combination also includes combining with a plurality of bioactive agents. In certain embodiments, the combination with a plurality of bioactive agents includes combining with a plurality of reagent monomers, each monomer coupled to at least one bioactive agent. In certain embodiments, the combination also includes combining with a plurality of targeting groups. In certain embodiments, the combination also includes combining with a plurality of stable monomers. In certain embodiments, the initiator is selected from a free radical initiator, a nucleophilic initiator, and an electrochemical initiator. In certain embodiments, the synthetic method disclosed herein also includes at least one purification step. In certain embodiments, the purification step is centrifugation. In certain embodiments, the purification step is filtration.
[0225] definition
[0226] Unless otherwise defined herein, the scientific and technical terms used in this application shall have the same meaning as commonly understood by those of ordinary skill in the art. Generally, the terms and techniques used in connection with chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry described herein are well known and commonly used in the art.
[0227] The methods and techniques in this disclosure are of general applicability, and unless otherwise indicated, the references and discussions in this disclosure refer to conventional methods well known in the art and specific methods specifically described in the references. For example, reference may be made to: "Principles of Neuroscience", McGraw-Hill Medical, New York, NY (2000); or Motulsky, "Intuitive Biostatistics", Oxford University Press, Inc. (1995); Lodish et al., "Molecular Cell Biology, Fourth Edition" WH Freeman & Co., New York (2000); Griffiths et al., "Introduction to Genetic Analysis, Seventh Edition", WH Freeman & Co., NY (1999); and Gilbert et al., "Developmental Biology, Sixth Edition" Sinauer Associates, Inc., Sunderland, MA (2000).
[0228] Unless otherwise defined herein, chemical terms used herein are defined according to conventional usage in the art, for example, in "McGraw-Hill Chemical Dictionary Terms", Parker S., Ed., McGraw-Hill, San Francisco, CA (1985).
[0229] The term "acyl" has the art-recognized definition of a group represented by the general formula hydrocarbyl C(O)-, preferably alkyl C(O)-.
[0230] The term "acylamino" is an art-recognized definition of an amino group substituted with an acyl group, and may be represented, for example, by the formula hydrocarbyl C(O)NH-.
[0231] The term "acyloxy" is an art-recognized definition of a group represented by the general formula hydrocarbyl C(O)O-, preferably alkyl C(O)O-.
[0232] The term "alkoxy" is an art-recognized definition of an alkyl group, preferably a lower alkyl group, to which oxygen is attached. Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy, and the like.
[0233] The term "alkoxyalkyl" is an art-recognized definition of an alkyl group substituted with an alkoxy group, and can be represented by the general formula alkyl-O-alkyl.
[0234] The term "alkenyl" is an aliphatic group containing at least one double bond as defined in the art, and shall include "unsubstituted alkenyl" and "substituted alkenyl", the latter referring to alkenyl groups having a substituted hydrogen on one or more carbons of the alkenyl group. Such substituents may be present on one or more carbons in one or more double bonds. Furthermore, as described below, these substituents include all substituents for alkyl groups unless stability is limited. For example, it is contemplated that alkenyl groups may be substituted with one or more alkyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups.
[0235] "Alkyl" or "alkane" is a straight or branched chain non-aromatic hydrocarbon that is fully saturated and has a generally accepted definition in the art. Typically, a straight or branched chain alkyl group has from about 1 to 20 carbon atoms, preferably from 1 to about 10 carbon atoms. Examples of straight and branched chain alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, amyl and octyl. A C1-C6 straight or branched chain alkyl group is also referred to as a "lower alkyl group".
[0236] In addition, the term "alkyl" (or "lower alkyl") used throughout the description, examples and claims is intended to include "unsubstituted alkyl" and "substituted alkyl", the latter referring to alkyl groups in which a hydrogen on one or more carbons of the hydrocarbon backbone is replaced by a substituent. If not otherwise specified, such substituents may include, for example, halogen, hydroxy, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl or acyl), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidino, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl or aromatic or heteroaromatic groups. According to the state of the art and the understanding of the skilled person, the groups on the hydrocarbon chain themselves may be substituted, designed to suit the reaction conditions. For example, the substituents of the substituted alkyl group may include amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate) and silyl substituted and unsubstituted forms as ether, alkylthio, carbonyl (including ketone, aldehyde, carboxylate and ester), -CF 3, -CN, etc. Exemplary substituted alkyl groups are described below. The cycloalkyl group may be further substituted by alkyl, alkenyl, alkoxy, alkylthio, aminoalkyl, carbonyl substituted alkyl, -CF 3, -CN, etc.
[0237] The term "Cx-y" when used in conjunction with a chemical group such as acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy refers to groups including those containing x to y carbons in the chain. For example, the term "Cx-y alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups including straight and branched chain alkyl groups containing x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc. Co-alkyl refers to positions where hydrogen is in the terminal position of the group, or internal if it is a bond. The terms "C2-y alkenyl" and "C2-y alkynyl" refer to substituted or unsubstituted unsaturated aliphatic groups similar in length and potential to the alkyl groups described above, but containing at least one double or triple bond, respectively.
[0238] The term "alkylamino" as used herein refers to an amino group substituted with at least one alkyl group.
[0239] The term "alkylthio", as used herein, refers to a thiol group substituted by an alkyl group, and can be represented by the general formula alkyl S-. As used herein, the term "alkynyl" refers to an aliphatic group containing at least one triple bond, and is intended to include "unsubstituted alkynyl" and "substituted alkynyl", the latter of which refers to an alkynyl moiety having a substituent replacing a hydrogen. On one or more carbons of the alkynyl group. Such substituents may appear on one or more carbons that are included or not included in one or more triple bonds. In addition, as described above, these substituents include all substituents considered for alkyl groups, unless they are not allowed in terms of stability. For example, it is contemplated that the alkynyl group may be substituted with one or more alkyl, carbocyclyl, aryl, heterocyclyl or heteroaryl groups.
[0240] As used herein, the term "amide" refers to a group
[0241]
[0242] Each R 10 independently represent hydrogen or a hydrocarbon group, or two R 10 Together with the N atom to which they are attached they form a heterocyclic ring having 4 to 8 atoms in the ring structure.
[0243] The terms "amine" and "amino" are art-recognized terms that define unsubstituted and substituted amines and salts thereof, such as moieties represented by the formula
[0244]
[0245] Each R 10 independently represent hydrogen or a hydrocarbon group, or two R 10 Together with the N atom to which they are attached they form a heterocyclic ring having 4 to 8 atoms in the ring structure.
[0246] The term "amidino" is an art-recognized group represented by the general formula Among them, R9 and R 10 Each represents a substituent, for example hydrogen or a hydrocarbon group, for example an alkyl group, an aryl group, a heteroaryl group, a cycloalkyl group or a heterocyclyl group.
[0247] As used herein, the term "aminoalkyl" is the art-recognized definition of an alkyl group substituted with an amino group.
[0248] The term "aralkyl" as used herein is the art recognized definition of an alkyl group substituted with an aryl group.
[0249] The term "aryl" as used herein is a monocyclic aromatic group that is substituted or unsubstituted, and each atom of the ring is carbon, as recognized in the art. Preferably, the ring is a 5- to 7-membered ring, and more preferably a 6-membered ring. The term "aryl" also includes polycyclic systems having two or more rings, wherein two or more carbon atoms are shared with two adjacent rings, wherein at least one ring is aromatic, for example, the other rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclyl. Aryl includes benzene, naphthalene, phenanthrene, phenol, aniline, etc.
[0250] The term "carbamate" is an art-recognized definition
[0251] Or
[0252] Where R 9 and R 10 independently represent hydrogen or a hydrocarbon group, such as an alkyl group, or R 9 and R 10 Together with the middle atom, a heterocyclic ring having 4 to 8 atoms in the ring structure is formed.
[0253] As used herein, the terms "carbocycle" and "carbocyclic" refer to a saturated or unsaturated ring in which each atom is carbon. The term carbocycle includes aromatic carbocycles and non-aromatic carbocycles. Non-aromatic carbocycles include cycloalkane rings in which all carbon atoms are saturated and cycloolefin rings containing at least one double bond. "Carbocycle" includes 5-7 membered monocyclic rings and 8-12 membered bicyclic rings. Each ring of the bicyclic carbocycle can be selected from saturated, unsaturated and aromatic rings. Carbocycles include bicyclic molecules in which one, two or three or more atoms are shared between the two rings. The term "fused carbocycle" refers to a bicyclic carbocycle in which each ring shares two adjacent atoms with another ring. Each ring of the fused carbocycle can be selected from saturated, unsaturated and aromatic rings. In an exemplary embodiment, an aromatic ring such as a phenyl ring can be fused to a saturated or unsaturated ring, such as cyclohexane, cyclopentane or cyclohexene. Any combination of saturated, unsaturated and aromatic bicyclic rings is included in the definition of carbocycle within the range allowed by the valence ring. Exemplary "carbocycles" include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane. Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-1H-indene and bicyclo[4.1.0]hept-3-ene. "Carbocycles" may be substituted at any one or more positions capable of bearing a hydrogen atom.
[0254] "Cycloalkyl" groups are fully saturated cyclic hydrocarbons, including monocyclic and bicyclic rings. Unless otherwise defined, monocyclic cycloalkyl groups typically have 3 to about 10 carbon atoms, more typically 3 to 8 carbon atoms. The second ring of a bicyclic cycloalkyl group can be selected from saturated, unsaturated and aromatic rings. Cycloalkyl groups include bicyclic molecules in which one, two or three or more atoms are shared between the two rings. The term "fused cycloalkyl" refers to a bicyclic cycloalkyl group in which each ring shares two adjacent atoms with another ring. The second ring of a fused bicyclic cycloalkyl group can be selected from saturated, unsaturated and aromatic rings. "Cycloalkenyl" groups are cyclic hydrocarbons containing one or more double bonds.
[0255] The term "carbocyclylalkyl" as used herein is the art recognized definition of an alkyl group substituted with a carbocyclyl group.
[0256] The term "carbonate" is defined as -O CO2-R 10 Group, where R 10 It represents a hydrocarbon group.
[0257] As used herein, the term "carboxyl" is the group represented by the art-recognized definition -CO2H.
[0258] As used herein, the term "ester" is the art-recognized definition of the group -C(O)OR 10 , where R 10 It represents a hydrocarbon group.
[0259] As used herein, the term "ether" is an art-recognized definition of a hydrocarbon group attached to another hydrocarbon group through an oxygen. Thus, an ether substituent of a hydrocarbon group may be hydrocarbon-O-. Ethers may be symmetrical or asymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-heterocycle. Ethers include "alkoxyalkyl" groups, which may be represented by the general formula alkyl-O-alkyl.
[0260] The term "guanidino" is an art-recognized general term. A group represented by 8 , R 9 and R 10 Each represents a substituent, for example hydrogen or a hydrocarbon group, such as an alkyl group, an aryl group, a heteroaryl group, a cycloalkyl group or a heterocyclyl group.
[0261] As used herein, the terms "halo" and "halogen" refer to halogens including chlorine, fluorine, bromine and iodine.
[0262] As used herein, the terms "heteroalkyl" and "heteroaralkyl" refer to an alkyl group substituted with a heteroaryl group.
[0263] As used herein, the term "heteroalkyl" refers to a saturated or unsaturated chain of carbon atoms and at least one heteroatom, wherein no two heteroatoms are adjacent.
[0264] The terms "heteroaryl" and "heteroaryl" include substituted or unsubstituted aromatic monocyclic structures, preferably 5 to 7 membered rings, more preferably 5 to 6 membered rings, whose ring structures include at least one heteroatom, most preferably 1 to 4 heteroatoms, more preferably one or two heteroatoms. The terms "heteroaryl" and "heteroaryl" also include polycyclic ring systems having two or more rings, wherein two or more carbons are common to two adjacent rings, and wherein at least one ring is heteroaromatic, for example, the other rings can be: cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclyl. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
[0265] As used herein, the term "heteroatom" refers to an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen and sulfur.
[0266] The terms "heterocyclyl", "heterocycle" and "heterocyclic" refer to substituted or unsubstituted non-aromatic ring structures, preferably 3 to 10 members, more preferably 3 to 7 members, whose ring structures include at least one heteroatom, most preferably 1 to 4 heteroatoms, more preferably one or two heteroatoms. The terms "heterocyclyl" and "heterocyclic" also include polycyclic ring systems having two or more rings, wherein two or more carbon atoms are common to two adjacent rings, wherein at least one ring is heterocyclic, for example, the other ring may be a cycloalkyl,
[0267] Cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclic. Heterocyclic groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactone, lactam, etc.
[0268] The term "heterocyclylalkyl" as used herein refers to an alkyl group substituted with a heterocyclyl group.
[0269] As used herein, the term "hydrocarbyl" refers to a group bonded by a carbon atom that does not have a =0 or =S substituent, and generally has at least one carbon-hydrogen bond and a primary carbon skeleton that may optionally include heteroatoms. Thus, for purposes of this application, groups such as methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be hydrocarbyl, but groups such as acetyl (with a =0 substituent on the connecting carbon) and ethoxy (connected by oxygen, not carbon) are not hydrocarbyl. Hydrocarbyl includes, but is not limited to, aryl, heteroaryl, carbocyclic, heterocyclic, alkyl, alkenyl, alkynyl, and combinations thereof.
[0270] The term "hydroxyalkyl" as used herein refers to an alkyl group substituted with a hydroxy group.
[0271] The term "hydrazine" is an art-recognized term defined by the general formula A group represented by 9 and R 10Each represents a substituent, for example hydrogen or a hydrocarbon group, such as an alkyl group, an aryl group, a heteroaryl group, a cycloalkyl group or a heterocyclyl group.
[0272] The term "lower" when used in conjunction with a chemical moiety such as acyl, acyloxy, alkyl, alkenyl, alkynyl or alkoxy refers to groups including those having ten or fewer non-hydrogen atoms in the substituent, preferably six or fewer. For example, "lower alkyl" refers to an alkyl group containing ten or fewer, preferably six or fewer carbon atoms. In certain embodiments, an acyl, acyloxy, alkyl, alkenyl, alkynyl or alkoxy substituent as defined herein is respectively a lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl or lower alkoxy, whether alone or in combination with other substituents, such as in the description, hydroxyalkyl and aralkyl (in this case, for example, when calculating the carbon atoms in the alkyl substituent, the atoms in the aryl group are not counted).
[0273] The term "phosphate" is an art-recognized general term. A group represented by 9 and R 10 Each represents a substituent, for example hydrogen or a hydrocarbon group, such as an alkyl group, an aryl group, a heteroaryl group, a cycloalkyl group or a heterocyclyl group.
[0274] The terms "polycyclic," "polycyclic," and "polycyclic" refer to two or more rings (eg, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclyl).
[0275] The terms "polycyclic", "polycyclic" and "polycyclic" refer to two or more rings (e.g., cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclyl) in which two or more atoms are common to two adjacent rings, e.g., "fused rings". Each ring of the polycyclic ring may be substituted or unsubstituted. In certain embodiments, each ring of the polycyclic ring contains 3 to 10 atoms in the ring, preferably 5 to 7 atoms.
[0276] The term "silyl" refers to a silicon moiety having three hydrocarbyl moieties attached thereto.
[0277] The term "siloxy" refers to an oxygen moiety bearing a silyl group.
[0278] The term "substituted" refers to a moiety in which a hydrogen atom on one or more carbon atoms on the skeleton is replaced by a substituent. It is understood that "substituted" or "substituted by..." includes the implicit condition that the substitution is based on the allowed valence of the substituted atom and the substituent, and that the substitution will produce a stable compound, for example, it will not spontaneously undergo transformation steps such as rearrangement, cyclization, elimination, etc. As used herein, the term "substituted" is intended to include all allowed substituents of organic compounds. In a broad sense, allowed substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. For suitable organic compounds, the allowed substituents may be one or more and the same or different. For the purposes of the present invention, heteroatoms such as nitrogen may have hydrogen substituents and / or any allowed substituents of organic compounds described herein that satisfy the valence of the heteroatoms. Substituents may include any substituent described herein, such as halogen, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl or acyl), thiocarbonyl (e.g., thioester, thioacetate or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidino, imine, imino, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, aminosulfonyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl or aromatic or heteroaromatic moiety. Substituents themselves may be substituted, designed to suit reaction conditions, according to the state of the art and the understanding of the skilled person. Unless specifically stated as "unsubstituted", chemical moieties referred to herein should be understood to include substituted variants. For example, reference to an "aryl" group or moiety implicitly includes substituted and unsubstituted variants.
[0279] The term "sulfate" is an art-recognized definition of the group -OSO3H or a pharmaceutically acceptable salt thereof.
[0280] The term "sulfonamide" is an art-recognized term defined as a sulfonamide having the general formula A group represented by 9 and R 10 independently represent hydrogen or a hydrocarbon group, such as an alkyl group, or R 9 and R 10 Together with the middle atom, a heterocyclic ring having 4 to 8 atoms in the ring structure is formed.
[0281] The term "sulfoxide" is an art-recognized definition of the group -S(O)-R 10 , where R 10 It represents a hydrocarbon group.
[0282] The term "sulfonate" is an art-recognized definition of the group SO3H or a pharmaceutically acceptable salt thereof.
[0283] The term "sulfone" is an art-recognized definition of the group -S(O)2-R 10 , where R10 Represents a hydrocarbon group.
[0284] The term "thioalkyl" as used herein is the art-recognized definition of an alkyl group substituted with a thiol group.
[0285] As used herein, the term "thioester" is the art-recognized definition of the group -C(O)SR 10 or -SC(O)R 10 , where R 10 It represents a hydrocarbon group.
[0286] As used herein, the term "thioether" is equivalent to an ether wherein the oxygen is replaced by sulfur.
[0287] The term "urea" is defined in the art as being a urea having the general formula Indicates that R 9 and R 10 independently represent hydrogen or a hydrocarbon group, such as an alkyl group, or R 9 and R 10 Together, the one or more intermediate atoms complete the heterocycle having from 4 to 8 atoms in the ring structure.
[0288] "Protecting group" refers to an atomic group that masks, reduces or prevents the reactivity of a reactive functional group in a molecule when attached to the functional group. Typically, the protecting group can be selectively removed as needed during the synthesis process. Examples of protecting groups can be found in Protecting Groups in Organic Chemistry by Greene and Wuts, 3rd edition, 1999, by John Wiley and Harrison, et al., New York, and in A Compendium of Synthetic Organic Methods, Vols. 1-8, 1971 to 1996, by John Wiley and his sons, New York. Representative nitrogen protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl ("CBZ"), tert-butyloxycarbonyl ("Boc"), trimethylsilyl ("TMS"), 2-trimethylsilyl-ethanesulfonyl ("TES"), trityl and substituted trityl, allyloxycarbonyl, 9-fluorenylmethoxycarbonyl ("FMOC"), nitroperoxycarbonyl ("NVOC"), etc. Representative hydroxy protecting groups include, but are not limited to, those in which the hydroxy group is acylated (esterified) or alkylated, such as benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (such as TMS or TIPS groups), glycol ethers, such as ethylene glycol and propylene glycol derivatives, and allyl ethers.
[0289] As used herein, the terms "degradable" and "non-degradable" refer to the ability of the polymers described herein to degrade into smaller fragments. In certain embodiments of the present invention, the degradable polymers can decompose at physiological pH values. In certain embodiments, the degradable polymers can decompose at about pH 7.4. In certain embodiments, a mixture of degradable and non-degradable polymers can produce a degradable polymer mixture. In certain embodiments, a mixture of degradable and non-degradable polymers can decompose at physiological pH. In certain embodiments, a mixture of degradable and non-degradable polymers can decompose at about pH 7.4.
[0290] Examples of positively charged monomers, crosslinkers, and neutral monomers are provided in U.S. Patent Application Publication Nos. Table 1, 2, and 3. U.S. Patent No. US2015 / 0071999, the entire contents of which are incorporated herein by reference.
[0291] As used herein, the term "targeting moiety" refers to a moiety (e.g., an antibody, a hormone, a hormone derivative, folate, a gene, a folate derivative, biotin, a molecule, an oligopeptide, a sigma-2-ligand, a cell membrane carbohydrate) that is used to target or direct the conjugate to a specific location (e.g., a cell type or a diseased tissue) or interaction (e.g., a specific binding event).
[0292] All other publications, patents, and published patent applications cited above in this application are expressly incorporated herein by reference. In the event of a conflict, the present specification, including specific definitions, will control.
[0293] The term "agent" as used herein refers to a compound (e.g., an organic or inorganic compound, a mixture of compounds), a biomacromolecule (e.g., a nucleic acid, an antibody, including portions thereof and humanized compounds) chimeras, human antibodies and monoclonal antibodies, a protein or portion thereof (e.g., a peptide, a lipid, a carbohydrate) or an extract made from a biological material (e.g., a bacterial, plant, fungal or animal (especially mammalian) cell), or a tissue. The agent includes, for example, an agent of known structure and an agent of unknown structure. The ability of such an agent to inhibit AR or promote AR degradation may make it suitable as a "therapeutic agent" in the methods and compositions of the present disclosure.
[0294] As used herein, the term "biologically active agent" refers to a substance that can be used in conjunction with a therapeutic or diagnostic application, for example, a method for diagnosing the presence or absence of a disease in a patient and / or a method for treating a disease in a patient. "Biologically active agent" refers to a substance that is capable of exerting a biological effect in vitro and / or in vivo. A biologically active agent can be neutral, positively charged, or negatively charged. Suitable biologically active agents include, for example, prodrugs, imaging agents, diagnostic agents, therapeutic agents, drugs, pharmaceuticals, oxygen delivery agents, blood substitutes, synthetic organic molecules, proteins, peptides, vitamins, steroids, steroid analogs, and genetic material, including nucleosides, nucleotides, and polynucleotides.
[0295] "Patient", "subject" or "individual" are used interchangeably and refer to human or non-human animals. These terms include mammals, such as humans, primates, livestock (including cattle, pigs, etc.), companion animals (such as dogs, cats, etc.) and rodents (such as mice and rats).
[0296] "Treating" a condition or patient means taking steps to obtain beneficial or desired results, including clinical results. As used herein and as is well known in the art, "treatment" is a method of obtaining beneficial or desired results, including clinical results. Beneficial or desirable clinical results may include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, alleviation of the extent of the disease, stabilization of the disease state (i.e., not worsening), prevention of the spread of the disease, delay or slowing of the progression of the disease, improvement or alleviation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" may also mean prolonging survival compared to expected survival if not receiving treatment.
[0297] The term "prevent" is art-recognized and when used in conjunction with a condition such as a locally recurrent (e.g., pain), a disease such as cancer, a syndrome such as heart failure, or any other medical condition, the administration of the composition can reduce the frequency of occurrence of the medical condition in a subject or delay its onset relative to a subject not receiving the composition. Thus, prevention of cancer includes, for example, a decrease in the number of detectable cancer cases in a population of patients receiving prophylactic treatment relative to an untreated control population, and / or a statistically and / or clinically significant increase in the time to detectable cancer in a treated population relative to an untreated population.
[0298] As used herein, the phrase "combined administration" refers to any form of administration of two or more different therapeutic agents, such that the second drug is administered while the previously administered therapeutic agent is still effective in the body (e.g., the two drugs are used simultaneously). Effective for the patient (possibly including a synergistic effect of the two drugs). For example, different therapeutic compounds can be administered in the form of the same formulation or separate formulations, such as concomitantly or sequentially. Therefore, individuals receiving such treatment can benefit from the combined effects of different therapeutic agents.
[0299] As used herein, "pharmaceutically acceptable salt" or "salt" refers to an acid addition salt or a basic addition salt that is suitable or compatible with the treatment of a patient.
[0300] The term "pharmaceutically acceptable acid addition salt" as used herein refers to any non-toxic organic or inorganic salt of any base compound. Exemplary inorganic acids that form suitable salts include hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include monobasic, dibasic and tribasic carboxylic acids such as glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, benzoic acid, phenylacetic acid, cinnamic acid and salicylic acid. Acids and sulfonic acids such as p-toluenesulfonic acid and methanesulfonic acid. Monoacids or diacids can be formed, and these salts can exist in hydrated, solvated or substantially anhydrous forms. Generally, acid addition salts of compounds are more soluble in water and various hydrophilic organic solvents, and generally exhibit higher melting points compared to their free base forms. The selection of suitable salts is known to those skilled in the art. Other non-pharmaceutically acceptable salts, such as oxalates, may be used, for example, when isolating the compound for laboratory use, or subsequently converted to a pharmaceutically acceptable acid addition salt.
[0301] As used herein, the term "pharmaceutically acceptable basic addition salt" refers to any non-toxic organic or inorganic base addition salt of any acid compound. Exemplary inorganic bases that form suitable salts include lithium, sodium, potassium, calcium, magnesium or barium hydroxide. Illustrative organic bases that form suitable salts include aliphatic, alicyclic or aromatic organic amines, such as methylamine, triethylamine and picoline or ammonia. The selection of suitable salts is known to those skilled in the art.
[0302] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filter, diluent, excipient, solvent or encapsulating material, which can be used to formulate a drug or a medicament for therapeutic use.
[0303] Example
[0304] The invention now being generally described, will be more readily understood by reference to the following examples which are intended merely to illustrate certain aspects and embodiments of the invention and are not intended to be limiting of the invention.
[0305] Example 1: Blood-brain barrier (BBB) penetrating protein nanoparticles complex delivery to the central nervous system
[0306] First, horseradish peroxide was coupled to N-acryloyloxysuccinimide (NAS) to attach acryloyl groups to its surface. The average number of acryloyl groups conjugated to the protein molecule was determined by measuring the residual (unreacted) lysine on the protein molecule using the fluorescamine assay, which was approximately 4.5.
[0307] After acryloyloxylation, the protein was encapsulated using an in situ polymerization method. MPC and the cross-linker bis-methylacrylamide (BIS) were first prepared as 40% (m / v) stock solutions in deionized water and 10% (m / v) in anhydrous DMSO, respectively. MPC and BIS were then encapsulated into a solution of HRP protein (1 mg / mL) at a molar ratio of 5000:1 (MPC to HRP protein) and 500:1 (BIS to HRP protein), respectively. The polymerization reaction was initiated by the addition of APS (300:1) and TEMED (1200:1) and maintained at 4°C for 2 hours. After polymerization, the solution was dialyzed against phosphate buffered saline (PBS) to remove unreacted monomers and by-products. Horseradish peroxide nanoparticles (nHRP) were further purified using a hydrophobic interaction column (phenyl-Sepharose CL-4B) to remove any unencapsulated horseradish peroxide. nHRP was examined using a transmission electron microscope (TEM) and showed a uniform spherical shape with an average diameter of -30nm. HRP nanoparticles were administered to non-human primates (macaques) at doses of 2.5, 5.0 and 10.0mg / kg by intravenous injection. After intravenous injection, plasma was collected every day for 2 weeks, and cerebrospinal fluid (CSF) was collected on days 1, 4, 7, 10 and 14. The circulation time of nHRP in plasma was prolonged and could be detected 2 weeks after injection. Cerebrospinal fluid (CSF) collected on the first day after intravenous injection of 10mg / kg n-HRP was examined using TEM, showing the presence of particles similar in morphology and size to nHRP. Since CSF contains almost no protein and the particle size is much larger than blood protein, the nanoparticles shown in the TEM images of CSF samples are nHRP that cross the BBB to CSF. This study clearly shows that nHPR is successfully delivered to CSF.
[0308] The concentration of n-HRP in plasma and cerebrospinal fluid was quantified by TMB substrate kit (Thermo Fisher Scientific, USA). On the first day, the concentration of nHRP in the CSF of macaques injected with 2.5mg / kg, 5.0mg / kg and 10.0mg / kg n-HRP was 5.57ng / mL, 24.17ng / mL and 68.21ng / mL, which was equivalent to 1.12%, 2.63% and 1.99% of the nHRP concentration in plasma, respectively. This shows that nHRP is delivered to CSF in a dose-dependent manner. On the 4th day after injection, the concentration of nHRP in CSF reached -5.3% of the plasma concentration.
[0309] Example 2: Delivery of Therapeutic Proteins to the Central Nervous System (CNS) of Monkeys
[0310] Nimotuzumab protein can be directly encapsulated by in situ polymerization without acrylation reaction. MPC was used as monomer. Poly(DL-lactide)-b-poly(ethylene glycol)-b-poly(DL-lactide)-diacrylic acid triblock copolymer (PLA-PEG-PLA diac) and glycerol dimethacrylate (GDMA) were used as degradable cross-linkers. MPC, PLA-PEG-PLA copolymer and GDMA were added to the nimotuzumab protein solution (2.2 mg / mL) at a molar ratio of 12000:1 (MPC to protein), 500:1 (PLA-PEG-PLA copolymer to protein) and 500:1 (from GDMA to protein). The polymerization reaction was initiated by adding APS (2000:1) and TEMED (8000:1) at 4°C for 3 h. After polymerization, the solution was concentrated with a centrifugal filter unit to remove unreacted monomers and by-products. The protein nanoparticles were further purified using a hydrophobic interaction column (phenyl-Sepharose CL-4B) to remove unencapsulated proteins.
[0311] To evaluate the delivery efficiency of the CNS, nimotuzumab nanoparticles were administered to non-human primates (rhesus monkeys) at a dose of 5.0 mg / kg by intravenous injection. After intravenous administration, plasma was collected on days 1, 2, 3, 5, 7, 10, 14 and 17 after injection, and CSF was collected on days 3, 10 and 17. Both nimotuzumab and nimotuzumab nanoparticles (n-Rituximab) showed the same long circulation time in rhesus macaque plasma. The cerebrospinal fluid concentration of monkeys taking natural nimotuzumab was significantly lower than that of monkeys using nimotuzumab nanoparticles (5-15 times higher). On the 17th day after a single intravenous injection, high concentrations of nimotuzumab were observed in the CSF of monkeys administered with nimotuzumab nanoparticles. In sharp contrast, monkeys administered with natural nimotuzumab could not detect nimotuzumab in the CSF before week 2.
[0312] Example 3: Treatment of brain tumors in mice
[0313] Nanoparticles of nimotuzumab (n(Nimotuzumab)) were synthesized using MPC and a peptide cross-linker with the amino acid sequence VPLGVRTK, which can be degraded by tumor proteases.
[0314] Nimotuzumab solution (5 mg / mL) was diluted to 1 mg / mL using phosphate buffer (20 mM, pH = 7.4) under ice bath. N-(3-aminopropyl) methacrylamide (APm) prepared in 100 mg / mL aqueous solution was added to the protein solution and stirred at 4°C for 10 minutes. APm was enriched around nimotuzumab through electrostatic and hydrophobic interactions. 2-Methacryloyloxyethyl phosphorylcholine and bisacrylylated VPLGVRTK peptide were added to the protein solution in sequence under rapid stirring. The molar ratio of MPC:APm:crosslinker was adjusted to 50:5:1. Free radical polymerization was initiated by adding ammonium persulfate dissolved in deionized water (total monomer molar ratio of 1:10) and an equal volume of 10% (w / v) N,N,N',N'-tetramethylethylenediamine to the free radical solution. The polymerization was carried out at 4°C in a nitrogen atmosphere for 90-120 minutes. Finally, unreacted monomers, cross-linkers and initiators were removed by dialysis in PBS (20 mM, pH = 6.5). After dialysis, the nimotuzumab nanoparticles were passed through a Sephadex G-200 column by gravity to remove unencapsulated nimotuzumab antibodies.
[0315] To establish an intracranial tumor model, U87-EGFRwt cells were infected with luciferase lentivirus (Genepharma, Shanghai, China). Two days after infection, 5×10 5 cells and injected them into the intracranial striatum of 5-week-old female nu / nu-nude mice using a stereotaxic apparatus. Mice were treated with natural nimotuzumab or nimotuzumab nanoparticles (5 mg / kg body weight, intravenous injection) every other day until 9 doses were given. Treatment began 3 days after tumor cell injection. In the control group, each animal was injected intravenously with 100IA of sterile PBS. There were 9 mice in each group. In order to obtain the tumor growth status of living animals in different treatment groups by bioluminescence imaging, mice were anesthetized, 50 mg / mL D-luciferin (Promega, China) was injected intraperitoneally, and imaged for 10-120 seconds using an IVIS imaging system (Caliper Life Sciences).
[0316] Compared with the control group and the natural nimotuzumab treatment group, the tumors of mice treated with nimotuzumab nanoparticles showed significantly inhibited progression. After the last injection (day 20), tumor-bearing brain tissues of each group were collected to finally confirm the therapeutic effect of nimotuzumab nanoparticles. HE staining results showed that compared with natural nimotuzumab treatment, nimotuzumab nanoparticle treatment showed a significant reduction in tumor growth.
[0317] Example 4: Delivery of protein conjugates
[0318] The protein conjugate was synthesized by coupling the polymer poly(2-methacryloyloxyethylphosphorylcholine) (PMPC) to fluorescently labeled bovine serum albumin (BSA). The BSA conjugate was injected into Balb / c mice at a dose of 5.0 mg / kg intravenously. On the first day after intravenous injection, the fluorescence intensity of the mouse brain was compared. The mice administered the conjugate showed a fluorescence intensity 6 times higher than that of mice injected with PBS, and a fluorescence intensity 4 times higher than that of mice injected with native BSA.
[0319] Example 5: Treatment of brain tumors in mice
[0320] The effectiveness of nimotuzumab delivery to brain tumors has been attributed to MPC containing choline and acetylcholine analogs. For verification, a series of nimotuzumab nanocapsules were synthesized by replacing 0%, 50%, and 100% of MPC monomers with vinylpyridine, a monomer used to synthesize nanocapsules with long circulation half-life but no BBB penetration ability. This series of nanocapsules contained different contents of MPC while having similar size and surface charge. Fig. 7A and 7B Depicted are in vivo bioluminescence images of mice with orthotopic U87-EGFRwt glioma xenografts and ex vivo fluorescence images of brain tissue collected 4 hours after intravenous administration of such nanocapsules. Treatment of mouse brains with similar tumor sizes with nanocapsules made with 100% MPC showed a 2.7-fold increase in fluorescence intensity compared to nanocapsules made with 50% MPC. No brain uptake was observed for mice treated with nanocapsules made with 0% MPC. This observation suggests that nanocapsules made with MPC
[0321] n(Nimotuzumab) is able to effectively deliver (Nimotuzumab) to brain tumors.
[0322] The BBB penetration of nanocapsules can be attributed to their endocytosis mediated by choline and acetylcholine receptors.Glioma-bearing mice were injected intraperitoneally with 1.25, 2.5 or 5 μg / kg of the choline transporter inhibitor hemicholinium-3 (HC-3) 20 minutes before the injection of Cy5.5-labeled n(Nimotuzumab). Fig. 8A and 8B In vivo bioluminescence images of orthotopic U87-EGFRwt glioma xenograft mice and ex vivo fluorescence images of the brain are depicted 4 hours after injection. Increasing doses of HC-3 significantly reduced the fluorescence intensity of the glioma brains, with no significant differences in tumor size or body weight, indicating that choline transporters mediate the transport of n(Nimotuzumab) into the brain. This approach provides an effective antibody delivery strategy for brain tumor therapy.
[0323] Example 6: Treatment of cerebral ischemia in rats
[0324] Acrylamide (AAm) with an average molecular weight of 2000Da (mPEG), N-(3-aminopropyl)methacrylamide (APm) and poly(ethylene glycol) methyl ether acrylate were dissolved in deoxygenated deionized DNase-free water and prepared as 10% (w / v) stock solutions. Anhydrous DMSO stock solution of glycerol dimethacrylate (GDMA) was prepared at 10% (w / v). Specific amounts of the above monomers and cross-linkers were then added to the miRNA solution, and the molar ratio of Aam / APm / mPEG / GDMA was adjusted to screen the synthesis parameters. The polymerization reaction was initiated by adding ammonium persulfate (1 / 10 molar ratio of total monomers) and N,N,N',N'-tetramethylethylenediamine (2 times the weight ratio of APS) and maintained at 4°C for 2 hours. The final miRNA concentration was adjusted to 5 μM by dilution with deoxygenated deionized DNase-free water. After polymerization, the solution was dialyzed against 10 mM PBS using a 10 kDa membrane to remove unreacted monomers and byproducts. Non-PEG n(miR-21) was synthesized by a similar method without the use of mPEG.
[0325] The rat model of transient focal cerebral ischemia was induced by middle cerebral artery occlusion reperfusion (MCAO / R). See the article by Liu et al. (2013) Biontaterials 34, 817-830. SD rats were anesthetized with 10% chlorine water (350 mg / kg, intraperitoneal (ip)). The body temperature was monitored and maintained at 37°C. A midline incision was made on the ventral side of the neck, and the muscles were gently pulled aside. Then, the right common carotid artery and the junction of the internal and external carotid arteries were carefully dissected. The external carotid artery was ligated and cauterized. A surgical nylon monofilament (0.234 mm in diameter), the tip of which was rounded by heating near a flame, was inserted into the internal carotid artery through the incision of the stump of the external carotid artery to block the origin of the middle cerebral artery. After 1 hour of ischemia, the filament was pulled out for reperfusion.
[0326] The in vivo application of miRNA nanocapsules in the treatment of cerebral ischemia has been demonstrated in a rat model of transient focal cerebral ischemia induced by middle cerebral artery occlusion reperfusion (MCAO / R). MiR-211 labeled with Cy5.5 (Cy5.5-miR-21) was used to synthesize Lipo / miR-21 and n(miR-21). Then, these two samples were intravenously injected on day 1 after ischemic injury at a dose of 0.5 mg / kg miR-21. 24 hours after administration, the accumulation of the two samples in the ischemic brain was analyzed using fluorescence imaging and qRT-PCR.
[0327] The fluorescence intensity in the head and isolated brain tissue of ischemic rats treated with n(miR-21) was higher than that of rats treated with Lipo / miR-21 ( Fig. 9A The radiative efficiency of miR-21 delivered by n(miR-21) or Lipo / miR-21 was quantitatively compared in ischemic and non-ischemic rats. Fig. 9B As shown, in ischemic rats, the radiation efficiency of n(miR-21) was 2-fold and 3.5-fold higher than that of Lipo / miR-21 and PBS controls, respectively, indicating that n(miR-21) has a higher radiation efficiency. The expression of miR-21 in postischemic brain tissue was further compared by qRT-PCR ( Fig. 9B ). The content of miR-21 in the ischemic brains of n(miR-21)-treated rats was 2.7-fold higher compared with that of Lipo / miR-21-treated rats, indicating that n(miR-21) enhanced the regulation of ischemia in the brain tissue compared with Lipo / miR-21.
[0328] FITC-labeled miR-21 was used to further understand the distribution of n(miR-21) in ischemic brain tissue. 24 hours after injection, the ischemic hemisphere of the brain tissue was isolated, fixed and stained. The fluorescence signal from n(miR-21) was much stronger than that from Lipo / miR-21, further confirming that the nanocapsules improved the delivery efficiency of miRNA in vivo ( Fig. 10A ). In addition, the distribution of the fluorescent signal from n(miR-21) matched the pattern of staining for nuclei and neuronal markers. Fig. 10B The delivery efficiency in neuronal cells was quantitatively and specifically analyzed in the study. n(miR-21) significantly improved neuronal delivery compared to Lipo / miR-21. The expression of miR-21 in brain tissues after delivery was further compared by qRT-PCR. The level of miR-21 was 2.7-fold higher in the brains of rats treated with n(miR-21) compared to those treated with Lipo / miR-21.
[0329] Neurological scores were evaluated 24 hours after MCAO / R to confirm that the transient focal cerebral ischemia model was successfully established in the experiment. See the article published by Liu et al. (2013) Biomaterials 34, 817-830. The experimenter conducted a double-blind experiment for behavioral assessment. Neurological deficits were scored according to the following description: 0, no deficit; 1, difficulty in fully extending the contralateral forelimb; 2, inability to extend the contralateral forelimb; 3, mild circling to the contralateral side; 4, severe circling and 5, falling to the contralateral side. Rats with neurological deficit scores of 1-3 were selected as models. After evaluating the neurological scores, the rats were anesthetized to death and brain slices were collected for HE staining to confirm that the transient focal cerebral ischemia model was successfully established.
[0330] like Fig.11 As shown, the mean neurological deficit scores of rats treated with PBS or n(miR-NC) improved only slightly over time; whereas the compound treated with n(miR-21) showed significantly improved performance. Brain tissues were collected on day 7 to assess infarct volume by 2,3,5-triphenyltetrazolium hydrochloride (TTC) staining. Fig.12 and 13 As shown, TTC-stained brains of rats treated with n(miR21) showed significantly reduced infarct volume (-45%) compared with rats treated with PBS or n(miR-NC).
[0331] Incorporation by reference
[0332] Any publications, patents, and patent applications mentioned herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. In the event of a conflict, the definitions contained in this application will control.
[0333] Principle of Equivalence
[0334] Although specific embodiments of the present invention have been discussed, the above description is illustrative rather than restrictive. By reading this specification and the following claims, a person skilled in the art may still propose various modifications and variations based on the present invention. The scope of protection of the present invention should be determined by reference to the claims, the specification, the full range of its equivalents and variants, and the changes included.
Claims
1. A polymer nanoparticle having increased permeability across the blood-brain barrier, comprising a cross-linked polymer matrix and a plurality of bioactive agents encapsulated in the matrix, wherein an initiator initiates cross-linking monomers and a cross-linking agent to encapsulate the bioactive agents through in situ polymerization, The cross-linking monomer is 2-methacryloyloxyethyl phosphorylcholine, N-(3-aminopropyl) methacrylamide, acrylamide or a combination thereof, The crosslinking agent is a triblock copolymer of poly(DL-lactide)-b-poly(ethylene glycol)-b-poly(DL-lactide)-diacrylic acid or glycerol dimethacrylate.
2. The polymer nanoparticle of claim 1, wherein the bioactive agent is non-covalently coupled to the polymer.
3. The polymer nanoparticle of claim 1 or 2, wherein the polymer further comprises a drug monomer, each drug monomer having a drug binding portion that is bound to the drug in a non-covalent coupling manner.
4. The polymer nanoparticle of claim 3, wherein the agent comprises a positively charged moiety and the agent monomer comprises a negatively charged agent binding moiety.
5. The polymer nanoparticle of claim 3, wherein the agent comprises a negatively charged moiety and the agent monomer comprises a positively charged agent binding moiety.
6. The polymer nanoparticle of claim 3, wherein the agent is hydrophobic and the agent monomer comprises a hydrophobic agent binding moiety.
7. The polymer nanoparticle of claim 1 or 2, wherein the polymer matrix is in the form of a polymer shell.
8. The polymer nanoparticles of claim 1 or 2, wherein the degree of crosslinking of the polymer nanoparticles is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%.
9. The polymer nanoparticle of claim 1, wherein the polymer comprises a stabilizing monomer.
10. The polymer nanoparticle of claim 9, wherein the stabilizing monomer comprises a polyethylene glycol unit.
11. The polymer nanoparticle of claim 9, wherein the stabilizing monomer comprises polyethylene glycol methacryloyl ester.
12. The polymer nanoparticle of claim 1 or 2, wherein the bioactive agent is a protein or a polynucleotide.
13. The polymer nanoparticle of claim 1 or 2, wherein the bioactive agent is an imaging agent.
14. The polymer nanoparticle of claim 1 or 2, wherein the bioactive agent is an antibiotic or an antiviral drug.
15. The polymer nanoparticles according to claim 1 or 2, wherein the bioactive agent is an anti-tumor drug.
16. The polymer nanoparticle of claim 1 or 2, wherein the bioactive agent is a growth factor, a cytokine, an antibody or an enzyme.
17. The polymer nanoparticle of claim 1 or 2, wherein the polymer nanoparticle comprises a plurality of targeting moieties.
18. The polymer nanoparticle of claim 17, wherein the targeting moiety is dissociated from the nanoparticle surface.
19. The polymer nanoparticle of claim 18, wherein the targeting moiety is covalently coupled to the nanoparticle.
20. The polymer nanoparticle of claim 18, wherein the targeting moiety is a targeting small molecule or a targeting protein.
21. The polymer nanoparticle of claim 1 or 2, wherein the polymer further comprises at least one hydrophilic portion.
22. The polymer nanoparticle of claim 21, wherein the hydrophilic portion comprises at least one hydrogen bond acceptor.
23. The polymer nanoparticle of claim 22, wherein the hydrogen bond acceptor is nitrogen or oxygen.
24. The polymer nanoparticle of claim 21, wherein the hydrophilic moiety is a neutral polymer.
25. The polymer nanoparticle of claim 21, wherein the hydrophilic moiety is covalently coupled to the polymer.
26. The polymer nanoparticle of claim 21, wherein the hydrophilic moiety is embedded or embedded in the polymer.
27. The polymer nanoparticle of claim 21, wherein the hydrophilic moiety is non-covalently bound to the polymer.
28. The polymer nanoparticle of claim 21, wherein the hydrophilic moiety is bound to the polymer via hydrogen bonding.
29. The polymer nanoparticle of claim 1 or 2, wherein the nanoparticle has a diameter of 5-20 nm.
30. The polymer nanoparticle of claim 1 or 2, wherein the topology of the polymer is linear, dendritic, star-shaped or multi-branched.
31. A drug complex comprising the polymer nanoparticles according to any one of claims 1 to 30 and a pharmaceutically acceptable excipient.
32. Use of the polymer nanoparticles according to any one of claims 1 to 30 in preparing a drug for treating brain tumors or cerebral ischemia.
33. The use of claim 32, wherein the tumor is a glioma.
34. The use as claimed in claim 32, wherein the polymer nanoparticles are administered intravenously.
35. The method for preparing polymer nanoparticles according to any one of claims 1 to 30, comprising a bioactive agent, a crosslinking monomer and a crosslinking agent, and initiating copolymerization with an initiator.
36. The method of claim 35, wherein the bioactive agent is selected from a protein or a polynucleotide.
37. The method of claim 35, wherein the biologically active agent is selected from an imaging agent.
